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Sphingolipids and ceramides are essential components of cellular membranes and 
important signalling molecules. Because of a growing appreciation for their diverse 
biological roles, understanding of the biosynthesis and regulation of sphingolipids 
has recently become a key goal in drug discovery. Serine palmitoyltransferase (SPT) 
is a pyridoxal 5-phosphate (PLP)-dependent enzyme that catalyses the condensation 
between L-serine and a long-chain acyl thioester such as palmitoyl-CoA (C16-CoA). 
This first step in sphingolipid biosynthesis is conserved in all organisms studied to 
date, from microbes to man. 
The fungal natural product myriocin is a potent inhibitor of SPT; however, the 
molecular details of inhibition are not fully understood. Myriocin contains a long 
alkyl chain and a polar head group thus it displays features of both SPT substrates. 
Therefore, the prevailing hypothesis is that inhibition of SPT occurs because 
myriocin acts as a mimic of a key transition state of the catalytic mechanism. 
Through a combination of UV-vis spectroscopy, mass spectrometry, x-ray 
crystallography and enzyme inhibition assays it has been possible to study the 
interaction between S. paucimobilis SPT and myriocin. I have shown that myriocin 
initially forms an inhibitory PLP:myriocin aldimine complex in the active site that 
displays a Ki of 967 nM. Interestingly, this complex is susceptible to unexpected, 
slow enzymatic degradation. The mechanism for myriocin breakdown has been 
elucidated as a retro-aldol type reaction, which results in cleavage of the C2-C3 bond 
producing a C18 aldehyde. This aldehyde is then capable of covalently modifying the 
active site lysine265, forming a second (suicide) inhibitory complex and rendering 
the enzyme catalytically inactive. 
Substitution of the active site lysine produced SPT K265A, an inactive enzyme that 
did not catalyse the breakdown of the PLP:myriocin complex. However, the 
determination of the crystal structure of the SPT K265A:PLP-myriocin complex 
revealed that the myriocin had undergone decarboxylation. Nevertheless, this 
SPT:PLP:decarboxymyriocin structure revealed details about myriocin’s mechanism 
of inhibition for the first time. The novel mechanism of myriocin degradation has 
 
 iii
implications on the structure activity relationship (SAR) and design of drugs targeted 
towards SPT, the role of feedback regulation by long chain aldehydes and further 
expands the range of reactions catalysed by this important enzyme. 
As well as inhibition studies the structure of bacterial SPT was also examined by 
preparing an N-terminally truncated S. paucimobilis SPT. This version, shortened by 
21 amino acids, was ~5-fold slower than the wild-type enzyme and suggests that the 
N-terminus may play a role in catalysis. Additional work has been undertaken to 
study an unusual membrane-bound viral SPT, composed of two naturally fused open 
reading frames (SPT2-SPT1) with the proposed SPT2 domain at the N-terminus and 
the SPT1 domain at the C-terminus. To study soluble mimics of this interesting 
fusion I prepared a bacterial S. paucimobilis SPT fused wild-type and mutant 
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1.1 Pyridoxal 5-phosphate 
Although pyridoxal 5′-phosphate (PLP) (Figure 1-1) is one of the less complex 
organic cofactors it has been shown to catalyse a large and varied range of reactions. 
PLP is known to play a role in over 160 enzymatic reactions with almost 1.5% of all 
genes in prokaryotes encoding for a PLP dependent enzyme.1 In contrast, the 
percentage of enzymes predicted to be PLP dependent in eukaryotes is decidedly 
smaller; probably due to two reasons – (i) PLP plays a more important role in basic 
metabolic pathways; and (ii) sequence variation making identification of PLP 
dependent enzymes difficult. Therefore the exact number of PLP-dependent enzymes 
in eukaryotes is unknown with new PLP dependent enzymes still being discovered.2-3 
PLP is part of the vitamin B6 group which consists of 6 vitamers, pyridoxal, 
pyridoxine and pyridoxamine and their phosphorylated forms (Figure 1-1). 
 
 
Figure 1-1 The six chemical forms of vitamin B6 
 
PLP is only synthesised in bacteria, plants and fungi but not by humans where it is 
acquired exogenously from their diets and enzymatic salvage pathways.4 Two de 
novo biochemical pathways are responsible for PLP synthesis; the pdx family and 
SOR1.5 Neither of these are known to occur in the same organism making them truly 
divergent. Pdx is an abbreviation for pyridoxine and is used to denote the genes and 
enzymes present in this PLP biosynthetic pathway. The pdx pathway consists of 6 


































characterised in E. coli. this family also exists in the plants and fungi.6 SOR1 was 
originally discovered by its ability to provide resistance to singlet oxygen species and 
was therefore denoted SOR for singlet oxygen resistance. However its ubiquitous 
nature and highly conserved sequence homology later led to the knowledge that it is 
also involved in PLP biosynthesis.5 Until recently it was believed an unusual 
precursor (1-deoxyxylulose 5-phosphate, dxp) was required for vitamin B6 synthesis 
by the pdx family of enzymes but it has now been elegantly shown that the 
precursors are readily available from glycolysis (glyceraldehyde 3-phosphate) and 
the pentose phosphate (ribose 5-phosphate or ribulose 5-phosphate) pathways.7-8 
Interestingly Pdx1 not only catalyses the majority of PLP formation but has also been 
shown to isomerise both the precursor pentose and triose to their most utilisable 
forms.9 A second enzyme (Pdx2) is required to generate ammonia from glutamine 
and facilitates its safe transport to the active site of Pdx1. A typical PLP biosynthetic 
route is summarised in Figure 1-2. 
 
 





















































































There are more than 160 chemical reactions catalysed by PLP which span a large 
range of chemistries including racemisation, decarboxylation, -elimination and 
substitution, transamination, -substitution and replacement and -elimination and 
substitution examples of each are given in Table 1-1. 
 
Table 1-1 Summary of PLP chemistries 
 
Despite the array of chemistry catalysed by the cofactor, PLP, the general catalytic 
mechanism remains consistent throughout. PLP is initially held in the active site via 
an imine bond with an active site lysine residue in what is commonly referred to as 
the covalent “internal aldimine”. The well established nomenclature also dictates that 
the PLP-free form of the enzyme is known as the “apo-form” while the PLP-bound 


















































































































form is referred to as the “holo-form”. Several other active site interactions have also 
been shown to be important for PLP binding including -stacking with aromatic 
residues above the PLP ring and hydrogen bonds to the pyrimidine nitrogen.18-19 
Upon substrate binding the internal aldimine is replaced by an imine formed between 
the amine of the substrate and PLP to produce the “external aldimine”. Additionally 
both the internal and external aldimines can exist in two tautomeric forms, a 
ketoenamine and an enolimine, which gives rise to the characteristic double maxima 
UV-vis spectrum (Figure 1-3). 
 
 
Figure 1-3 PLP binding in S. paucimobilis SPT 
Top – Chemistry of PLP binding to both enzyme and substrate. Internal aldimine and external 
aldimine in both tautomeric forms. Bottom – UV-vis spectrum of 40 M S.paucimobilis SPT 
Enolimine and ketoenamine absorb at 330 and 420 nm respectively.  
 
The chemistry catalysed by PLP extends impressively far from the known electron 
sink capabilities of the pyridine ring. The -elimination and substitution reactions are 
made possible by double proton extraction allowing conjugation to continue out to 
the -carbon. This extension of the conjugated system coupled with the formation of 
a reactive enamine at the -carbon allows reactions to proceed. All the above 


















































promoted by surrounding amino acids but PLP is also capable of catalysing reactions 
with no enzymatic assistance.  
 
The initial discovery of the non-enzymatic dependent activity by pyridoxal was made 
by Metzler and Snell in 1952.20-22 It was found that pyridoxal could transaminate 
amino acids to produce pyridoxamine and a keto-acid with the mechanism being 
completely elucidated through the extensive use of UV-vis spectroscopy.23 Although 
non-enzymatic, these reactions all required a metal ion to chelate to the 3-hydroxy 
and the imine nitrogen. Pyridoxal is also capable of decarboxylating the -carbon 
without the need of an enzyme, albeit slowly. This process follows a similar 
mechanism to transamination, where a chelated metal ion holds the system planar 
and aids the movement of the electrons into the pyridine ring.24 Controversially, 
Toney et. al have since shown that the metal ion is not required for catalytic activity 
and only aids Schiff base formation when experiments are performed in non-
saturating conditions.25 More recently organic chemists have adapted pyridoxal and 
have now produced a pyridoxal based system capable of racemising amino acid 
derivatives which could be coupled with another enzyme in a dynamic kinetic 
resolution method.26 
 
As previously mentioned, the chemical versatility of PLP is derived from its 
structure, which has been extensively studied. The vast array of information available 
now provides greater understanding of PLP chemistry and allows for accurate 
predictions of new reactivity based upon robust chemical understanding. PLP 
structure and its relation to function can be split into two categories. Firstly the 
stereoelectronic aspect, based largely around a hypothesis forwarded by Dunathan, 
and secondly the chemical structure, i.e. functional group incorporation and location. 
 
Dunathan first proposed his stereoelectronic rationale for PLP activity in 1966.27 His 
hypothesis was based upon hyperconjugation and can be used to predict which bond 
is to be broken in any specific reaction, if the three-dimensional arrangement of the 
substituents is known. The basic premise of Dunathan’s work is that the chemistry 
PLP will perform is determined initially by the breaking of whatever -carbon bond 
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is perpendicular to the PLP ring (Figure 1-4). The perpendicular sigma bond is 
weaker due to hyperconjugation and the transition state is also lower in energy due to 
the developing p-orbital being in optimal position for conjugation into the -system. 
To date, the Dunathan hypothesis has held true - with all published structures so far 
confirming the theory.  
 
Figure 1-4 Dunathan Intermediate 
PLP is drawn perpendicular to the plane of the page with thick bold bonds pointing towards the reader 
and thin bonds pointing away. P orbitals have been added to show the possible overlap and 
hyperconjugation. The weakened α-carbon bond has been highlighted. 
 
To date, the 2-methyl group of PLP is the only functional group, of the five (methyl, 
pyridine nitrogen, aldehyde, hydroxyl and phosphate), not to have been extensively 
investigated and its importance shown. Nevertheless until its role is systematically 
analysed its importance can only be hypothesised. The methyl group has the potential 
to both change the electronics of PLP, by donating electrons inductively onto the 
ring. As well as the obvious steric affects such as the ability to subtly change 
conformation and thus influence enzyme selectivity. Most recently the role of the 
phosphate in PLP was analysed in our research group by Beattie et al., showing for 
the first time that the phosphate of PLP can be used to orientate the -carbon 
substituents.28 In the structure of the S. paucimobolis serine palmitoyltransferase 
(SPT) PLP:L-serine external aldimine, the phosphate group of PLP was shown to 
hydrogen bond to the hydroxyl group of L-serine, limiting rotation around the 
nitrogen--carbon bond.29 This nuance of PLP chemistry came from the close 
examination of PLP crystal structures and partially explains the amino acid 
specificity of SPT.29  
 
The aldehyde moiety of PLP is universally accepted as essential; ever since the initial 
understanding of PLP mechanisms and the requirement for imine formation in both 
the internal and external aldimine was known, therefore its importance cannot be 







OP Weakened sigma bond
 
 8
to form Schiff bases, has prompted the use of acetone and other ketones in 
comparison studies with PLP.31-33  
 
The role of the hydroxyl group in PLP has not been probed with most of the 
discussion focussing on whether the oxygen remains protonated and what affect this 
has on the electronics of the ring.31 In the early days of PLP chemistry, the C3 
hydroxyl group was shown to be catalytically essential in non-enzymatic reactions.24 
The use of several C3 derivatives produced no active compounds and was the basis 
for the hypothesis that the hydroxyl group hydrogen bonded to the imine nitrogen. 
Indeed a hydrogen bond between the C3 hydroxyl and the imine nitrogen has been 
confirmed by recent enzyme crystal structures.29 The pyridine ring was always 
thought to provide the basis for PLP chemistry due to the belief that it formed an 
electron sink. Pyridine was believed to be the ideal electron sink as it is more 
electron deficient than benzene, due to the electronegative nitrogen. The electron 
withdrawing capacity could be increased further by protonation of the nitrogen thus 
producing an even more electron deficient ring. Not long after the discovery of the 
catalytic capability of PLP it was widely understood that the pyridine nitrogen 
needed to be protonated to allow C deprotonation, this hypothesis has now been 
shown not to be correct for all PLP-dependent enzymes.34 Toney et al. demonstrated 
that the protonated nitrogen and the extra electrophilic capacity that follows is only 
required in PLP reactions where a 1,3-prototropic shift is required (Figure 1-5).  
 
 
Figure 1-5 Example of a 1,3-prototropic shift 
Movement of a proton from the α-carbon to the β-carbon of PLP. The shift occurs via a quinanoid 
intermediate and is catalysed by a near-by base allowing nucleophilic attack onto the α-carbon and 






























Toney suggests that for PLP reactions not requiring this shift the carbanion 
stabilisation offered through the Schiff base/imine is sufficient. An example of a 
reaction that requires a 1,3-prototropic shift is a transamination whilst racemisations 
and eliminations do not require such a rearrangement. 
  
As further proof of the effect variation in electrophilicity has upon reaction outcome 
Toney et al. used 1-deazapyridoxal-5´-phosphate (deazaPLP, Figure 1-6); a PLP 




Figure 1-6 The structure of 1-deazapyridoxal-5´-phosphate (deazaPLP)  
 
Substitution of PLP for deazaPLP decreased the catalytic activity for all the enzymes 
used in this study but crucially only the reactions that required a protonated pryridine 
nitrogen e.g. reactions that required 1,3-prototropic shift demonstrated a compete 
lack of function. These findings imply that the “electron sink” capabilities of PLP 
can be partially fulfilled by any aromatic system with only a few PLP catalysed 






1.2 PLP dependent enzymes 
PLP-dependent enzymes are classified by their tertiary structure and are split into 5 
categories, or fold-types (type I, II, III, IV and V) (Figure 1-7). It was initially 
hypothesised that the enzymes function was related to its fold-type but over time and 
with the publication of more structures this has since been shown not to be true.35-36  
 
 
Figure 1-7 Representations of the five different fold types of PLP enzymes 
Each monomer is coloured differently and PLP is shown in spacefill with carbons in yellow. Top 
Left. Fold Type I - E. coli aspartate aminotransferase; PDB code: 1ASN. Top Middle. Fold Type II - 
Salmonella typhimurium O-acetylserine sulfhydrylase; PDB code: 1OAS. Top Right. Fold Type III - 
Bacillus stearothermophilus alanine racemase; PDB code: 1SFT Bottom Left. Fold Type IV - 
Thermophilic Bacillus sp. D-amino acid aminotransferase; PDB code: 1DAA. Bottom Right. Fold 
Type V – Rabbit glycogen phosphorylase; PDB code: 1GPA 
 
Type I Type II Type III 
Type IV Type V 
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Fold type I is the largest sub class of PLP dependent enzymes and also the most 
diverse class.37 Within this large sub class exists the -oxoamine synthase (AOS) 
family or CoA-dependent acyltransferases which constitutes a small but still growing 
family of enzymes many of which play important biological roles as summarised in 





Table 1-2 Members of the AOS family
Enzyme Amino acid Thioester Product Pathway PDB Code 
Serine Palmitoyltransferase 
 (SPT) 
L-serine Palmitoyl CoA 3-ketodihydrosphingosine (KDS) Sphingolipid SP apo: 2JGT 
SP holo: 2JG2 
SP L-serine:PLP: 2W8J 
SW holo: 2X8U 
SM L-serine:PLP: 3A2B 
2-amino-3-ketobutyrate-CoA ligase 
(KBL) 
Glycine Acetyl-CoA 2-amino-3-ketobutyrate (AKB) Threonine degradation EC holo: IFC4 
CB holo: 3TQX 
5-aminolevulinate acid synthase 
(ALAS) 
Glycine Succinyl-CoA 5-aminolevuliante (ALA) Tetrapyrrole RC holo: 2BWN 
RC glycine:PLP: 2BWP 
RC succinyl-CoA:PLP: 2BWO 
8- amino-7-oxononanoate synthase 
(AONS) 
L-alanine Pimeloyl-CoA 8-amino-7-oxononanoate (AON) Biotin EC apo: 1BSO 
EC holo: 1DJE 
EC AON:PLP: 1DJ9 
Cholerae CAI-1 Synthase  
(CqsA) 
L-threonine or
, L-2-aminobutyric acid or 
(S)-adenosylmethionine 
Decanoyl-CoA Cholera autoinducer-1 (CAI-1) Quorum sensing VC apo: 2WK7 
VC holo: 2WK8 
VC L-threonine:PLP: 2WK9 
VC Decanoyl-CoA:PLP: 2WKA 
Legionella LAI-1 Synthase (LqsA) - - - - - 
Janthionbacterium JAI-1 Synthase 
(JqsA) 
- - - - - 
Seryl transferase (SerT/PigH) L-serine Pyrrolyl-β-ketoacyl-S-ACP 4-hydroxy-2,2’-bipyrrole-5-methanol 
(HMB) 
Prodigiosin - 
Fumonisin8 (Fum8) L-alanine Steroyl-ACP  Fumonisin - 
SaxitoxinA (SxtA) Arginine Proponoyl-CoA Saxitoxin intermediate Saxitoxin - 
5-aminolevulinate synthase (Orf34) Glycine Succinyl-CoA 5-aminolevulinate (ALA) (cyclase) 2-amino-3-hydroxycyclopent-2-
enone polyketide (C5N) 
- 
TambjamineD (TamD) L-serine Malonyl-CoA Tamjamine intermediate Tamjamine - 




The discovery of sphingolipids is accredited to Johann Ludwig Wilhelm Thudichum, 
a German born medical doctor and biochemist, in 1884.38 Upon discovery 
Thudichum noted the compounds were "...of an alkaloidal nature, and to which, in 
commemoration of the many enigmas which it has presented to the inquirer, I have 
given the name of Sphingosin." The naming of the compounds after the puzzling 
Egyptian creature the sphinx has remained and upon elucidation of the structure of 
sphingosine in 1947 by Carter et al. it was decided to name “ ... those lipids derived 
from sphingosine as sphingolipids.”39-40 This definitively non-systematic/IUPAC 
nomenclature has led to some confusion in the literature; however a sphingolipid is 
generally recognisable from the amino diol (or sometimes triol) head group 
connected to a long alkyl chain (Figure 1-8). More specifically the configuration of 
the sphingoid base of which sphingosine, dihydrosphingosine or phytosphingosine 
(Figure 1-8) are three examples can be used to help identify the host organism e.g. 
dihydrosphingosine is the major base in mammalian cells while phytosphingosine is 
the principal base in plants, yeast and fungi, but some crossover does exist.41 
 
Figure 1-8 Structure of the three sphingoid bases along with the most widely known 







































Figure 1-9 Abbreviated mammalian sphingolipid biosynthetic pathway42 
The series of enzymatic steps that constitutes the sphingolipid de novo biosynthesis in mammals. Serine palmitoyltransferase (highlighted in green) 
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The first and rate limiting step of sphingolipid biosynthesis (Figure 1-9), in all 
organisms studied to date, is the condensation of L-serine with palmitoyl coenzyme 
A, which is catalysed by the enzyme SPT. SPT is the rate limiting step in de novo 
sphingolipid biosynthesis and is also a key sphingolipid regulator as excess 
sphingosine inhibits SPT activity.43 There are a few variations in SPT specificity 
with the most common being the variation in acyl-Coenzyme A chain length.44-45 It is 
thought that the product of the SPT-catalysed reaction, 3-ketodihydrosphinganine 
(KDS), never accumulates to appreciable levels in cells as the rate of KDS reductase 
(KDSR) is substantially faster than that of SPT.46 However, there is potential for this 
reduction step to be slowed under oxidative stress.47 Independent of whether 
sphingosine is sequestered into the ceramide synthase pathway or phosphorylated by 
sphingosine kinase, the only exit point from the sphingolipid pathway is by cleavage 
of sphingosine-1-phosphate (S1P). The enzyme S1P lyase (S1PL) breaks the C2-C3 
bond to form phosphoethanolamine and hexadecenal in what is now known to be an 
irreversible manner.48-49 S1PL is a PLP-dependent enzyme in the fold type 1 sub 
family and thus displays the characteristic UV-Vis absorbances and well understood 
chemistry of similar PLP enzymes. This has aided the elucidation of the enzyme’s 
structure and mechanism and it is now known that S1P is broken down via a retro-
aldol type reaction, but the identity of the base required for deprotonation is as yet 
unknown.50-52 Upon exiting the sphingolipid pathway there seems some ambiguity as 
to the role of hexadecenal and phosphethanolamine. Hexadecenal can be metabolised 
to palmitate then palmitoyl-Coenzyme A, which could be recycled into sphingolipid 
biosynthesis.53 The recycling of the sixteen-carbon alkyl chain back into the 
sphingolipid pathway is believed to explain the increase in ceramide levels upon over 
expression of S1PL.54 The role of phosphethanolamine is even more complex again 
as this product goes on to be incorporated into the phospholipid pathway thus linking 
the sphingolipid and phospholipid biosynthetic pathways.55 
 
Through the work of the NIH-funded Lipid Maps consortium a repository has been 
created for newly discovered lipids and now has in the region of 4300 documented 
sphingolipids.56 Free sphingoid bases themselves are rarely found in nature, with 
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most sphingolipids consisting of a sphingoid base linked to a fatty acid via an amide 
bond to form ceramides (Figure 1-8 and Figure 1-9), which themselves can be 
glycosylated into increasing larger and more complex molecules (Figure 1-10).57 
Figure 1-10 Examples of more complex sphingolipids  
GM2  levels are raised in melanomas and has been investigated as a possible target for new 
chemotherapies. 58 GD2 has been linked to Tay-Sachs disease, a disease of the nervous system that is 
caused by build-up of excess GM2/GD2 in the brain.59 
 
It was initially thought that sphingolipids played only structural roles, along with 
other lipids, in membranes but it is now known that they are involved in a much 
wider plethora of cellular functions. Even within membranes the role of 
sphingolipids is not simple. Due to their predominantly saturated alkyl tails, 
sphingolipids pack more effectively with cholesterol forming lipid rafts, more rigid 
cholesterol and sphingolipid enriched regions of the membrane.60 As research 
continues sphingolipids have now been shown to be involved in all major disease 
areas, including cancer, diabetes, Alzheimer’s and asthma. S1P, probably the most 
widely known sphingolipid (Figure 1-11), is a known regulator of cell growth and 
delays programmed cell death.61 There are 5 characterised human S1P nuclear 
receptors and all are members of the large, medicinally important G-protein coupled 
receptor (GPCR) family. Leading on from these discoveries, S1P has been 
investigated extensively as a possible oncology target and has led to one isoform of 
sphingosine kinase (SK1) being denoted an “oncogene” as it is overexpressed in 
multiple cancers.62 The importance of the kinase is compounded by sphingosine 
promoting cell death whereas S1P promotes cell survival and has prompted more 
than thirteen distinct new therapeutics developments specifically targeting the S1P 
pathway, with the most famous of these being FTY720 (Fingolimod; trade name 
Gilenya, Novartis) (Figure 1-11).62 This drug is now being used clinically as the first 
GM2 Ganglioside GD2 Ganglioside 
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oral, disease-modifying agent approved by the Food and Drug Administration (FDA) 
to reduce relapses and delay disability progression in patients with relapsing forms of 
multiple sclerosis.  
 
Figure 1-11 The structure of sphingosine-1-phosphate (S1P) and FTY720, a synthetic 
pharmaceutical derived from myriocin but found to block S1P receptors 
 
The observation that obese individuals are more likely to develop diabetes was 
proven long before the biochemical explanation was elucidated. However it is now 
believed that an increase in free fatty acids drives sphingolipid biosynthesis (Figure 
1-9) producing an excess of ceramide.63 Ceramide is capable of blocking several of 
the key steps in glucose uptake, which insulin is supposed to activate, including 
inhibiting the phosphorylation of the Insulin Receptor Substrate-1.64  
It seems pertinent that, as sphingolipids were first discovered in the brain 130 years 
ago, they have recently been linked to Alzheimer’s disease. In the brain the first step 
of sphingolipid biosynthesis varies slightly, with both palmitoyl and stearoyl-CoA 
being condensed to increase the variety in the sphingolipid pool. The proportion of 
sphingolipids containing the additional two carbons increases with cell age and 
varies depending upon sphingolipid type.65 The molecular understanding of the roles 
sphingolipids play in disease is relatively limited due to their variation and multiple 
modes of action with confusion being compounded by the changing quantity and 
structure of sphingolipids with age.66-67 Three such sphingolipid anomalies found in 
the brain of Alzheimer patients include: (i) a decrease in more complex 
ganglosides;68 (ii) an increase in 18-carbon alkyl chains in proportion to the more 
common 16-carbon69 and (iii) the presence of a sphingolipid binding domain on the 
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conclusively linked to asthma, through both small molecules72 and genetically.73 A 
large scale genome comparison aimed at elucidating the origin of childhood asthma 
compared DNA from asthmatics and non-asthmatics and successfully mapped single 
base pair mutations only present in asthma suffers. These mutations clustered on 
chromosome 17 at q21 and resulted in up regulation of ORMDL3.74 ORM proteins 
are now known to negatively regulate the activity of SPT.73 When the ORM protein 
is phosphorylated there is low SPT activity but this rate can also be conversely 
increased by dephosphorylation of the ORM, see Figure 1-12. 
 
Figure 1-12 Regulation of yeast SPT activity by ORM proteins75 
SPT subunits Lcb1, Lcb2 and Tsc3 form a complex with the proteins Orm1and Orm2. When cellular 
sphingolipid levels are plentiful, Orm proteins act as negative regulators of LCB synthesis. But when 
sphingolipids are in short supply, multi-site phosphorylation of Orm proteins gradually relieves their 
inhibitory activity, thereby restoring sphingolipid homeostasis. 
The importance of sphingolipids cannot be overstated and although they play many 
important roles, as is demonstrated in the four diseases above, there are still no 
commercially available sphingolipid modulating therapies, with the only 
breakthrough occurring with multiple sclerosis and FTY720. This is mainly due to 
the complexity of both sphingolipid biosynthesis and metabolism but also the variety 
of reactions that involve sphingolipids requiring any potential sphingolipid inhibitor 
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1.4 Serine palmitoyltransferase 
 Discovery of SPT 
SPT is the first enzyme in the de novo sphingolipid biosynthetic pathway. SPT was 
first isolated from yeast in the laboratories of Snell and Stoffel in 1970.76-77 Initially 
SPT had several names including 3-keto-dihydrosphingosine synthetase and 3-keto-
dihydrosphinganine synthetase before SPT was adopted in line with the IUPAC 
nomenclature.78 Snell also progressed the development of a new SPT assay based on 
monitoring CO2 production from carbon-14 labelled L-serine.76 Interestingly, this is 
in contrast to nearly all the other published assays, which monitor activity by the use 
of radioactive labelled substrates and TLC. Initial studies by Snell and Stoffel 
demonstrated SPT activity in yeast and later that year Braun and Kanfer found the 
first SPT activity in mammals through microsomal preparations of mouse and rat 
brains.79-80 Characterisation of SPT was initially attempted from microsomal 
preparation with kinetic analysis, substrate scope and pH dependence all being 
investigated.78-79 However, working with impure enzyme in unknown concentrations 
was not reliable.  
The genes responsible for SPT activity were initially found in yeast through the use 
of auxotrophic mutants and were denoted lcb1 (long chain base 1) and then lcb2 
corresponding to their order of discovery.46, 81 Until this point the structure of SPT 
was completely unknown and the discovery of two genes needed for SPT activity 
complicated the initial work. The similarity of LCB1 and LCB2, the proteins coded 
by the lcb genes, was 21% with both showing some similarity to 5-aminolevulinic 
acid synthase (ALAS) and to 2-amino-3-ketobutyrate coenzyme A ligase (KBL).82-83 
Interestingly, only lcb2 contained the conserved lysine residue required to bind PLP. 
However, as expression of both proteins together led to a 2.5 fold increase in activity 
the existence of a heterodimeric complex was correctly hypothesised. Building upon 
the work of Lester et al., Stoffel managed to cloned and successfully overexpressed 
both mouse and human LCB1 and LCB2 proteins.84 The cloning and overexpression 
of the two SPT subunits marked a major step forward in the detailed understanding 
of how SPT functioned, with the relatively low concentrations of SPT protein thus 
far hampering detailed mechanistic studies. Through this work the location of SPT in 
the endoplasmic reticulum (ER) was confirmed and the PLP binding lysine was also 
confirmed to exist only in LCB2, by mutagenesis studies. The function of LCB1 and 
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its relationship to LCB2 was complicated by the reported increase in SPT activity 
only being dependent on LCB2 expression. The uncertainty over the role of LCB1 in 
the SPT complex was solved the following year by Hanada et al.85 Hanada showed 
the heterodimeric nature of mammalian SPT for the first time by observing that both 
LCB1 and LCB2 co-purified from Chinese hamster ovary (CHO) cells when using 
only affinity-tagged LCB1. The result was then confirmed by antibodies for LCB2 
immunoprecipitating both proteins.  
The purification of eukaryotic SPT remained elusive even after the discovery of the 
responsible genes due to the added complexity of a multi-enzyme system; which 
requires dual expression and purification, as well as each subunit containing at least 
one hydrophobic membrane spanning domain.41, 86 One attempted purification of 
note involved the use of an immobilised SPT inhibitor, myriocin, on a solid phase 
support pulling out both LCB1 and LCB2 from the lysate of murine cytotoxic T 
lymphocyte cells (CTLL-2). Unfortunately, the quantities of enzyme purified where 
very small due to the expense and technical difficulty of producing a myriocin resin 
and unfortunately the purified enzyme was inactive.  However, as the main impetus 
of this work was to conclusively determine the in vivo target of myriocin, the 
ingenious approach by Schreiber and colleagues must be applauded.87 In 2000 
Hanada et al. doubly labelled lcb1 with both a hexa-his and a FLAG® tag and, for the 
first time, managed to isolate 1.2 g of twice purified, active lcb1/lcb2 complex.88 
The use of FLAG® affinity chromatography and sucrose monolaurate as a detergent 
appear to be two of the critical elements in this purification.  Indeed FLAG® affinity 
chromatography is still used today to purify the mammalian SPT complex.89 The 
addition of two tags onto a protein could have affected the enzymatic efficiency; 
however, comparison of pH studies and substrate scope  analysis are all in line with 
earlier results published from microsomal SPT studies. Hanada has undertaken a 
comprehensive acyl-CoA substrate specificity study of mammalian SPT from CHO 
cells that shows the substrate specificity for palmitoyl-CoA is reasonably tight; 
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Acyl-CoA % KDS formed 
Myristoyl (14 carbons) 13.0 ± 1.4 
Pentadecanoyl (15 carbons) 73.1 ± 1.1 
Palmitoyl (16 carbons) 100 ± 4 
Heptadecanoyl (17 carbons) 61.9 ± 5.4 
Stearoyl (18 carbons) 11.1 ± 0.8 
Arachidoyl (20 carbons) <2 
 
Table 1-3 Acyl CoA specificity of purified mammalian SPT from CHO cells88 
 
The biosynthesis of sphingolipids has continued to bring new challenges as it was 
found that the activity of the yeast SPT heterodimer is increased by the presence of a 
small protein, Tsc3p.90 This 80 amino acid protein was discovered by Dunn et al. and 
found to increase SPT activity up to 30 fold. Unfortunately it was unclear exactly 
how much the rate was enhanced by the addition of Tsc3p as some of the difference 
in activity was attributable to the known substrate inhibition caused by palmitoyl-
CoA.91 Nevertheless Tsc3p undoubtedly increases the rate of KDS production 
significantly; and mutant Tsc3p-deficient yeast cells are unable to grow at elevated 
temperatures, thus demonstrating their inability to make sufficient KDS to sustain 
life. Following the discovery of a small activating subunit of SPT in yeast, similar 
proteins were sought in mammals, specifically humans, but sequence analysis 
yielded no results. Through the transfection of yeast LCB1/LCB2 deficient mutants 
with their human homologs, hLCB1 and hLCB2, Dunn and colleagues used a similar 
thermo-sensitive screening technique to test a human DNA expression library. This 
work led to the successful isolation of two small proteins that promote SPT activity 
in humans.44 The two small subunits, ssSPTa and ssSPTb, were 71 and 76 amino 
acids long respectively. Although similar to each other (45% identity) they shared no 
similarity with Tsc3p, both ssSPTa and ssSPTb contain two proposed membrane 
spanning domains. More interestingly the catalytic enhancement of the human 
lcb1/lcb2 complex by either small subunit is over 100 fold. Surprisingly, however the 
addition of either of these small subunits to the SPT complex can also alter the chain 
length specificity of SPT. Dunn and co-workers showed that various combinations of 
lcb1 with the different isoforms of lcb2 and either of the small subunits produced 
various proportions of product each with a different acyl chain length (Figure 1-13).  
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Figure 1-13 Varying SPT activity from different combinations of lcb1, lcb2 and small subunit 
Activity was measured in microsomes prepared from yeast expressing each of 
the 4 isozymes using [3H]serine and acyl-CoAs of the indicated (C12–C20) chain 
lengths.44 
 
Again progression in the understanding of eukaryotic KDS production was led by a 
discovery in yeast; independently, the groups of Weissman73, 89 and Chang92 
discovered that Orm1 and Orm2 (orm stands for orosomucoid) bind to the SPT 
complex and negatively regulate SPT activity. The proposed model of regulation 
involves the Orm proteins binding to SPT and inhibiting activity, this inhibition is 
then stopped by phosphorylation of the Orms in response to low sphingolipids levels 
(Figure 1-12). The role of Orm proteins in SPT regulation was initially discovered 
through epistatic mini-array profiles, which involves the comprehensive mapping of 
phenotypes to known mutations, which allowed catastrophic mutations in Orm1 and 
Orm2 to be linked to lcb1 and lcb2 knockouts.93 The link between SPT and the Orm 
proteins was confirmed after purification of either Orm 1 or 2 with the aid of a 
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Figure 1-14 Orm proteins form a complex with serine palmitoyltransferase 
Colloidal-comassie stained gels are shown for yeast proteins eluted after affinity purifications from 
strains expressing FLAG®–Orm1 or FLAG®–Orm2.93 
 
The presence of Sac1, a phosphatase, along with the other four proteins gave rise to 
the terms SPOTS complex, serine palmitoyltransferase, Orm 1/2, Tsc3, Sac1. The 
discovery of the SPOTS complex in yeast was thought to predict the existence of a 
similar arrangement in higher eukaryotes. Indeed it was already know that the human 
equivalent to the Orm proteins, ORMDLs, bind to human SPT.73 Lack of ORMDL 
expression leads to an increase in sphingolipids but direct evidence of their 
regulatory role is not available. 94-95  
In contrast to eukaryotes, sphingolipids are only found in a select group of bacteria, 
most of which are anaerobic.96 Some of the earliest investigations of bacterial 
sphingolipid production was also undertaken by Stoffel et al. using the knowledge 
gained through study of the eukaryotic system.97 The first attempt at purification of 
bacterial SPT was made from Bacteroides melaninogenicus by Lev et al. in 1981.98 
This was only partially successful, but the isolated SPT was subjected to kinetic 
analysis and the Km for L-serine was determined to be 1.13 mM, which very closely 
matches recent published results. In 2001 Ikushiro and colleagues chose to 
investigate the known sphingolipid-containing organism Sphingomonas paucimobilis 
and isolated the wild type SPT from soluble bacterial extracts. They succeeded in 
isolation of sufficient quantities of pure SPT which was then subjected to protein 
mass fingerprinting and N-terminal sequencing. Based on this data, they carried out a 
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reverse genetic analysis and generated degenerate DNA primers. This allowed them 
to clone the S. paucimobilis gene and prepare recombinant SPT in E. coli. This 
bacterial SPT showed high sequence homology to eukaryotic lcb1 and lcb2 as well as 
other members of the AOS family.99 In contrast to the eukaryotic enzyme,  bacterial 
SPT is encoded by a single gene and is a soluble homodimer. The 48% similarity of 
bacterial SPT and lcb2 coupled with good solubility and the homodimeric nature 
made bacterial SPT the ideal model for the more complex eukaryotic system. The 
ability to readily express and purify active SPT led to the promise of a high 
resolution x-ray crystal structure,99 which finally arrived from Campopiano et al. in 
2007 in collaboration with Jim Naismith in St. Andrews (Figure 1-15).100 The first 
evidence based visualisation of SPT elegantly showed the homodimeric nature of 
SPT, the location of the active site at the dimer interface, the location of the 
conserved PLP binding residues, confirmation of the presence of magnesium and 
highlighted the structural similarity between SPT and other AOS family members.  
Figure 1-15 The first crystal structure of S.paucimobilis SPT in its natural homodimeric form  
One monomer is coloured red and the other blue. The PLP in each monomer is shown in spacefill with 
the carbons in yellow, the two magnesium ions are shown in gray. PDB Code 2JG2. 
 
The positions of the Catoms in the protein backbone of SPT were compared to 8-
amino-7-oxononanoate synthase (AONS, PDB code 1DJE),101 2-amino-3-
ketobutyrate CoA ligase (KBL, PDB code 1FC4)102 and 5-Aminolevulinate 
Synthase, (ALAS, PDB code 2BWN).103 The root-mean-squared deviation (RMSD) 
between SPT and AONS was 1.6 Å, 1.4 Å between STP and KBL and 1.5 Å between 
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SPT and ALAS. The majority of structural diversity between the four enzymes is in 
the remote N-terminal regions.  
Following the publication of the x-ray structure, mutagenesis,29, 104 inhibition105-106 
and further mechanistic studies29 all quickly followed. Although the important 
residues for PLP binding can be observed via the lack of evolutionary variability 
through sequence alignments with other PLP binding enzymes, their proximity and 
location in SPT can now be confirmed. The widely reported group of PLP binding 
residues can be seen in Figure 1-16 and the individual functions of PLP binding for 
each residue can now be assigned – residues are numbered based on the S. 
paucimobilis SPT sequence. His 159 sits above the PLP ring and adds a -stacking 
interaction, Asp 231 is in the correct position to stabilise the protonated nitrogen of 
the PLP ring, as discussed earlier. His 234 is within H-bonding distance of the 
hydroxyl group on carbon-3 of the PLP ring.107 It has been clearly demonstrated 
through both crystal structures (PDB code 2JG2) and through mutation studies that 
lysine 265 binds PLP. From comparison of the internal aldimine structure of SPT 
(PDB code 2JG2) with the external aldimine structure (PDB code 2W8J) lysine 265 
is obviously very flexible, having moved more than 4 Å from PLP. (Figure 1-16) 
 
Figure 1-16 Active Site of SPT and the bound PLP:L-Serine external aldimine complex 
Showing the four key residues involved in PLP binding. PLP is captured as the external aldimine form 
with L-serine. Monomers are coloured blue and red. Important side chains are highlighted as sticks 
with carbon atoms coloured blue, nitrogen darker blue, oygen red and phosphorus orange. The PLP-L-
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Viruses were not known to contain sphingolipids until the successful sequencing of 
the Coccolithovirus genome in 2005 showed putative sphingolipid producing 
enzymes.108 Interestingly, the virus contains a single gene encoding for an 870 amino 
acid SPT with the C-terminal region showing similarity to the eukaryotic lcb1 and 
the N-terminal region showing similarity to lcb2.109 This natural fusion shows a 
unique preference for myristoyl-CoA (14 carbons) and produces the corresponding 
shorter (C16) sphingolipids in larger quantities. The catalytic ability also seems to 
have diminished through fusing both subunits together with the viral enzymes only 
showing a tenth of the activity of the wild-type yeast SPT proteins. Nevertheless, the 
existence of a natural fusion gave rise to the concept of man-made SPT fusions with 
the hope that the expression and purification of a single SPT would be more 
achievable. To date recombinant forms of both yeast and human lcb2-lcb1 head-to-
tail fusions have been successfully produced in microsomal preparations but only 
exhibit roughly a third of the activity of the natural enzymes.109 
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 SPT Mechanism 
Following the publication of the structure of sphingosine40 hypotheses were proposed 
as to its biosynthesis, with the first insight coming in 1953.110 Zabin et al. used 
carbon-14 labelled acetate to inoculate rats before extracting sphingolipids from their 
brain and analysing the carbon-14 content in a chemically astute, but now relatively 
crude, experiment. Zabin discovered that only carbons 3-18 of sphingosine were 
derived from acetate but acetate was shown four years later only to be the precursor 
of palmitoyl-Coenzyme A.111 Further experiments by Sprinson et al. used carbon-14 
in partnership with deuterium and nitrogen-15 labelling to determine that the head 
group carbons came from L-serine. (Figure 1-17).112  
 
 
Figure 1-17 Proposed synthesis of sphingosine and the preceding ketone 
Acetate-CoA and malonyl-CoA are the substrates for fatty acid synthase to produce Plamitoyl-CoA 
which condenses with L-serine to produce a ketone intermediate. The ketone intermediate is then 
reduced to form sphingosine. 
 
Following determination of serine as the second substrate Sprinson also deduced the 
formation of a ketone intermediate before reduction to the target molecule, 
sphingosine (Figure 1-17). The existence of a long chain keto intermediate between 
L-serine/palmitoyl-CoA and sphingosine was further expected from what was known 
of PLP chemistry;91, 113 however, the identification of the reductase responsible was 
not made until 1968.47  
Once the substrates for sphingosine biosynthesis had been elucidated the molecular 
details of the enzymatic reaction were investigated. PLP was identified as a cofactor, 
shortly after in 1958111 and was confirmed by the production of sphingolipids being 
inhibited by cysteine, a well-known PLP inhibitor.91 Incorporating the well 
characterised chemistries of PLP with the known starting materials and product, the 
following Schiff base, decarboxylation and/or deprotonation mechanism shown in 
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Figure 1-18 Initial proposed mechanisms for sphingosine biosynthesis 
 
Both of the above proposed mechanisms involved decarboxylation at some stage; 
therefore in order to determine which was correct, the ability to monitor the -proton 
of L-serine throughout the course of the reaction was required. Replacement of the 
-proton of L-serine with tritium provided a window into the active-site; and studies 
initially suggested the -hydrogen was retained during sphingosine synthesis.113 The 
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only plausible mechanism for the formation of the proposed carbanion. Although in 
his paper Weiss leaves open the possibility that another mechanism might be 
responsible, but does not suggest what that may entail. Eventually Krisnangkura et 
al.114 repeated the labeling experiments with L-serine and, through a combination of 
better techniques, concluded that the ‐proton of L-serine was lost and then replaced. 
The strongest evidence to support the order of deprotonation to generate the 
carbanion, condensation with the acyl-thioester then decarboxylation of the -keto 
acid intermediate was provided by Ikushiro et al. in 2008. Using elegant NMR 
experiments Ikushiro and colleagues managed to monitor the -carbon of L-serine 
during the course of a reaction. This allowed them to conclude that deprotonation did 
precede decarboxylation but deprotonation was controlled by binding of the second 
substrate, palmitoyl-CoA.115 Interestingly palmitoyl-CoA has repeatedly been shown 
to exhibit substrate inhibition at high concentrations.42, 91 Upon addition of the 
second substrate palmitoyl-CoA the reaction preceded so rapidly that monitoring was 
impossible on the NMR timescale. Therefore a special thioether palmitoyl-CoA 
analogue (S-(2-oxoheptadecyl)-CoA, Figure 1-26) was designed that contained an 
extra methylene bridge between the carbonyl and the sulfur thus breaking the 
thioester linkage and making loss of free CoA unlikely at physiological conditions. 
Using the palmitoyl CoA analogue allowed the rate of hydrogen-deuterium exchange 
at the -carbon to be monitored after both substrates were bound and showed a 100 
fold increase in exchange compared to before the addition of palmitoyl-CoA, thus 
demonstrating the increased stability of the resulting carbanion. The rationale for the 
rate enhancement observed upon palmitoyl-CoA binding remains only theoretical, as 
the fast turn-over of substrates has prevented any L-serine:palmitoyl-CoA:SPT co-
crystals being obtained. The use of the same palmitoyl-CoA mimic (Figure 1-26), as 
used in the NMR experiments above, made obtaining a L-serine:palmitoyl-CoA:SPT 
crystal structure a possibility; though, to date, no crystal structure of this tertiary 
complex is available. However, a model of S-(2-oxoheptadecyl)-CoA in the active 
site suggests the binding causes conformational change that pushes the -proton of 
the L-Serine:PLP aldimine perpendicular to the ring and therefore favourable for 
deprotonation. Combining more than 50 years of mechanistic studies has produced a 
widely accepted and detailed reaction mechanism for SPT (Figure 1-19).  
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Figure 1-19 Accepted SPT mechanism 
Proposed PLP-dependant catalytic mechanism of SPT. The internal aldimine (holo-SPT) is displaced 
by L-serine to form the external aldimine. Binding of the second substrate, palmitoyl-CoA, causes 
conformational change to give the Dunathan intermediate. This conformation allows deprotonation of 
Cα hydrogen by Lys265, forming the quinonoid. This is followed by nucleophilic attack from the Cα 
on to the palmitoyl-CoA thioester, releasing CoASH and forming the β-keto acid intermediate. This 
intermediate undergoes decarboxylation, before release of the product 3-ketodihydrosphingosine 
(KDS) and regeneration of the internal aldimine. 
 
For the correct sphingolipids to be produced in any organism, the serine based polar 
head group must be introduced in this first step and so SPT must be exquisitely 
specific for L-serine as a substrate. Interestingly several mutations have been 
discovered in human SPT that further broaden the reaction specificity allowing L-
alanine and glycine to replace L-serine thereby producing deoxysphingolipids 
(doxSAs). It is thought that these aberrant products build up in the body due to a lack 
of metabolic pathways for their degradation.116 This is due to deoxysphingolipids 
being unable to be phosphorylated by any kinase and therefore cannot be degraded 
by the S1P lyase. Several genetic mutations in the human SPT gene have been 
catalogued which display this phenotype and are associated with the extremely rare 
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 SPT Inhibitors 
Sphingolipids have been implicated in the progression of several disease states and 
inhibition of the sphingolipid pathway has been proposed as a novel therapeutic 
strategy for treatment of several diseases. As SPT catalyses the first and rate limiting 
step in sphingolipid biosynthesis, SPT is a particularly attractive target for inhibition. 
Initially inhibition studies of SPT utilised well known PLP inhibitors such as 
cysteine.76, 78 More recently, SPT specific natural product inhibitors have been used 
to probe the role of sphingolipids in vivo as well as a biochemical tool in vitro to 
allow the sphingolipid pathway to be paused while investigations are undertaken.73, 
92, 117 The newfound relationship between SPT and the human ORMDL proteins has 
produced another potential therapeutic interest in SPT inhibitors.68 The negative 
regulation of SPT by the ORMDL proteins, which themselves have been mapped to 
asthma suffers,118 gives rise to the hypothesis that mutations in ORMDL may cause a 
loss of function. Any loss of function would lead to disregulation of SPT and a build-
up of downstream sphingolipids; which could be responsible for the increased 
prevalence of asthma.  
A more definite link has been made between sphingolipid production and both 
hepatitis B and C. Both hepatitis B and C are class 3 pathogens (on a scale of 1-4) 
but preliminary studies suggest they can be treated with myriocin, an SPT specific 
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Interestingly the therapeutic effect of myriocin is now thought not to derive from the 
inhibition of SPT but its sphingolipid like structure. Comparative studies with 
FTY720, a myriocin derived drug that does not inhibit SPT but mimics sphingosine 
gave the same therapeutic effect.121 Still more promisingly, SPT inhibition has been 
convincingly linked to improvements in cancer treatments. From the discovery that 
sphingolipid levels were raised in several cancersmyriocin has been tested as a 
known specific SPT inhibitor.122-123  These studies have shown myriocin can cause 
tumour regression through lower sphingolipid levels and increased p53 activity even 
in the most aggressive forms of cancer.122-124  It has also been shown that ceramides, 
down stream products of sphingolipid biosynthesis, have direct effects on insulin 
signalling components which has linked sphingolipids and SPT to diabetes.125 Again 
through the use of myriocin preliminary evidence shows SPT inhibition can prevent 
defects in glucose metabolism and improved glucose tolerance in obese mice.126-127 
Finally but by no means exhaustively, sphingolipids have been connected to 
Alzheimer’s due to their high concentration in neuronal membranes but as yet this 
work has yet to progress to using specific sphingolipid inhibitors to further probe 
their role in this disease.67, 128  
SPT is without doubt a target for the pharmaceutical industry, with Lilly, Pfizer and 
Bayer as well as smaller BioTech companies openly declaring interest in this area 
through the publication of research papers and patents.129-132 However, as yet, no 
company has managed to progress any synthetic compounds into the clinic; therefore 
most of the work on inhibition of SPT has been driven by natural product discoveries 
(Figure 1-20Error! Reference source not found.). Sphingofungin B, myriocin, 
lipoxamycin and, to some extent, viridofungin A, all share the same general 
structural core as sphingosine. The slight modifications on the aliphatic tail seem to 
play an important role in gaining increased inhibitory activity, but the 
stereochemistry at carbon-14 does not seem to be crucial.133 Hanada et al. also made 
several analogues of sphingofungin B, systematically inverting the stereocentres at 
the head group and proved the crucial importance of all the chiral centres.133 
Sphingofungins were initially identified from Aspergillus fumigatus as broad 
spectrum antifungal agents that were noted for their lack of antibacterial activity.134 
The lack of antibacterial activity exhibited by sphingofungins led to the hypothesis 
that sphingofungin B was an inhibitor of sphingolipid biosynthesis as most bacteria 
do not produce sphingolipids. The identification of sphingofungin B as a specific 
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SPT inhibitor was achieved by adding back different sphingolipid intermediates to 
see when cellular viability was rescued, along with radio labelled substrates and 
specific SPT assays which gave sphingofungin B an IC50 of 20 nM.135 
 
Viridiofungin A (Figure 1-20Error! Reference source not found.) was isolated 
from Trichoderma viride as a very minor product and although initially wrongly 
classed as a squalene synthases inhibitor; it was later discovered to selectively inhibit 
sphingolipid biosynthesis.136 The Viridiofungin family is a very small group of 
compounds with their relatively small structural diversity arising from variations of 
the amide side chain, resulting in several of the family inhibiting SPT. Both tritium 
labelled palmitate and L-serine were used in SPT activity assays with viridiofungin 
A; which was found to have an IC50 of 22 nM in the correct strain of yeast cells. 
Wide variation in inhibition across different strains of yeast was noted and in 
Saccharomyces cerevisiae viridiofungin A inhibits several pathways at the 
micromolar level. Structure activity relationship (SAR) studies demonstrated that the 
length and saturation of the alkyl chain had only a modest effect on potency while 
substitution of the unusual extra acid group at C1 led to a 30 fold decrease in activity.  
Lipoxamycin (Figure 1-20Error! Reference source not found.) is the least 
spingosine-like natural product inhibitor of SPT but still exhibits remarkable potency 
with an IC50 of 21 nM in the correct strain of yeast.137 Unfortunately, the different 
structural features of lipoxamycin have not been investigated through any sort of 
SAR studies.  
Myriocin (Figure 1-20Error! Reference source not found.) is undoubtedly the best-
known SPT inhibitor; it has been well characterised and is widely utilised in studies 
of sphingolipid biosynthesis. Myriocin was first discovered in 1972 from two 
different thermophilic fungi by both Kluepfel et al. and Aragozzini et al.138-139 Whilst 
working with Myriococcum albomyces, Kluepfel isolated, purified and determined 
the structure of a previously unknown antimicrobial agent which was named 
myriocin. In this early study the lack of antibacterial activity was noted along with 
potential solubility problems that arose during the first in vivo analysis of myriocin. 
In the same year Aragozzini published details of the same compound which was 
isolated from Mycelia sterilia and called Thermozymocidin. The stereochemical 
configuration of myriocin was published a year later following complex 
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derivatisation to aid NMR assignment of the chiral centres.140 A small molecule 
crystal structure was attempted with myriocin but the project only managed to 
crystallise the N-acetyl-lactone derivative (Figure 1-21).141 
 
 
Figure 1-21 Crystallisable N-acetyl--lactone myriocin derivative 
 
Myriocin is now commercially available (from Sigma-Aldrich) having been 
fermented from the parent fungus. As well as the natural product, two total synthesis 
methods have been published with the first method utilising the similar 
stereochemistry of D-fructose as a starting material.142-143 Over 20 years after its 
initial isolation myriocin was re-isolated in 1994 under the name ISP-1 form Isaria 
sinclairii due to its potent immunosuppresent activity.144 Kawasaki and colleagues 
determined an IC50 value of 15 nM, using CTLL-2 cells as a model for myriocin 
dependent inhibition of cell growth and elimination of ceramide production.145 Since 
growth was restored by the addition of sphingosine, it suggested that SPT was the 
primary target of myriocin. In 1999 Schreiber and colleagues used a myriocin-like 
affinity resin to confirm the two subunits of murine SPT (lcb1 and lcb2) as the 
primary targets of the natural product myriocin.87 The known immunosuppressant 
activity of myriocin is unlikely to stem from its inhibition of SPT, otherwise all SPT 
inhibitors would show some immunosuppressant characteristics. Nevertheless, 
comparison of myriocin to other known immunosuppressants such as cyclosporine A 
and tacrolimus have shown it to exhibit remarkably high activity, despite its 
comparatively simple structure. Myriocin is consistently more active than 
cyclosporine A and inhibits the production of T-cell dependent antibodies at least ten 
fold more successfully.144 The differences in activity were rationalised by the 
suggestion that myriocin and cyclosporin A acted upon different pathways. 
Cyclosporin A was a known inhibitor of the production of the signalling molecule, 
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Structure activity studies on myriocin have shown that the unusual carbonyl group at 
carbon-14 on the alkyl tail of myriocin is not required for activity.146 While NaBH4 
reduction of the ketone to the corresponding alcohol produced no change in activity 
but the Clemmensen reduction to produce the corresponding methylene produced a 
10 fold increase in activity. Conversely reduction of the double bond decreased the 
immunosuppressant activity by an order of magnitude.  
 
The efficacy of myriocin as an immunosuppressor or indeed for the treatment of any 
condition is severely limited by its low solubility, which led Fujita and colleagues to 
try and find more pharmaceutically suitable alternatives. In 1995 FTY720 (Figure 1-
22) was published utilising the information that the myriocin C14 carbonyl moiety 
was unnecessary along with extensive simplification via the removal of the three 
chiral centres and partially locking the movement of the alkyl chain by the 
introduction of an aromatic ring.147-148 
 
 
Figure 1-22 FTY720 (Fingolimod) 
 
FTY720 remains almost equipotent in the same immunosuppresant assays but the 
chemical modifications made to myriocin on route to FTY720 have removed all SPT 
inhibition activity. The lack of SPT inhibition along with the persistence of 
immunosuppressant activity is further evidence for SPT inhibition not being the 
cause of the immunosuppressant activity displayed by myriocin. The mode of action 
of FTY720 has now been traced to its structural similarity to sphingosine. This 
similarity allows it to be phosphorylated and then act as an agonist for the four G-
protein coupled sphingosine-1-phosphate receptors thus pushing FTY720 into the 
pro-drug category as it must be activated in vivo before it is effective.149  
 
Intriguingly, the mode of action of myriocin upon SPT remains largely unknown. It 
has been assumed that myriocin forms an external aldimine with PLP due to the 
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Figure 1-23 Proposed myriocin-PLP intermediate 
 
Some excellent mechanistic work has also been carried out on the mode of action of 
L and D-cycloserine (Figure 1-20Error! Reference source not found.) as an SPT 
inhibitor, aided by SAR data obtained from a crystal structure.106 From this data 
Lowther et al. showed that SPT effected a ring-opening, then decarboxylation of 
cycloserine to generate PLP and an amino aldehyde adduct (Figure 1-24). This is in 
contrast to other PLP dependent enzymes where an isoxazole-PMP derivative is 
formed from the initial PLP-cycloserine aldimine via deprotonation at C-.  
 
Figure 1-24 Cycloserine inhibition 
Top – Cycloserine interacting with PLP bound to alanine racemase and forming the expected inactive 
3-hydroxyisoxazole PMP derivative. Bottom – Cycloserine interacting with PLP bound in SPT, 
catalysisng the conversion of PLP to inactive PMP. 
 
Again through the detailed understanding of PLP chemistry Beattie et al. elucidated 
the mechanism of SPT inhibition by L-penicillamine.105 Coupling previous 
knowledge gained from crystal structures along with historical PLP literature which 
details in-depth UV-vis analysis of PLP and its intermediates, Lowther elucidated 
that L-penicillamine inhibits SPT by rendering PLP inactive by the formation of a 
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Figure 1-25 L-Penicillamine inhibition of SPT 
 
The production of the thiazolidine-PLP adduct was confirmed by elegant native mass 
spectrometry analysis which showed the adduct either present in one or both of the 
active sites. Both the studies with cycloserine and L-penicillamine show how in-
depth understanding of PLP coupled with the use of an array of complex techniques 
is required to understand the versatile catalytic activity of SPT. β-chloro-alanine 
(Figure 1-20Error! Reference source not found.) is another example of a broad 
spectrum PLP inhibitor, but at the correct concentrations, can also act as a selective 
SPT inhibitor.150 Studies by Medlock show that inhibition of SPT is achieved with a 
much lower concentration of β-chloro-alanine than was required for inhibition of 
other PLP-dependent enzymes.151 Inhibition of SPT can be achieved with 5 mM, 
while no inhibition of aspartate or alanine aminotransferases was seen at that level.  
Studies with excess L-serine have shown that L-serine and β-chloro-alanine, 
unsurprisingly, compete for the same site. This hypothesis is further substantiated by 
the highly enantioselective binding of β-chloro-alanine, with the L conformation 
exhibiting 20 times more potency than β-chloro-D-alanine. Binding at the PLP 
binding site of the enzyme would also explain the broad spectrum of PLP inhibition. 
The utility of β-chloro-alanine is limited even with the most potent conformation, as 
even β-chloro-L-alanine only has an IC50 of 1 mM, which is far too high for use in 
vivo. 
The only published man-made SPT inhibitor is a modification of the palmitoyl-CoA 
substrate (Figure 1-26), which was first synthesised by Ikushiro et al. as a tool for 
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Figure 1-26 S-(2-Oxoheptadecyl)-CoA (Palmitoyl CoA Analogue ) 
 
The only difference between the 2-oxoheptadecyl-CoA analogue and palmitoyl-CoA 
is the addition of a methylene linker between the sulfur and the end carbonyl. This 
important addition halts the mechanism after deprotonation, just before nucleophilic 
attack of the Cα onto the palmitoyl-CoA substrate (Figure 1-19). The extra carbon 
results in the leaving group having a carbanion, not the more stable sulfur anion. The 
instability of the leaving group means the reaction no longer proceeds and stops at 
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2 Aims 
Having introduced the field of sphingolipid chemistry and biology and reviewed the 
key role that the first enzyme, SPT, plays in the pathway this thesis has the following 
aims: 
1. To understand the molecular details of how myriocin interacts with and 
inhibits SPT. Initially the myriocin-SPT relationship was probed through 
examination of inhibition kinetics but the ultimate goal was to produce a 
myriocin-SPT co-crystal structure, which could then be used to guide future 
drug development. 
 
2. To probe the role of the N-terminus in SPT. 
 
3. To continue the work on development of fusion SPT proteins. 
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3 Materials and Methods 
3.1 Materials and Reagents 
Unless otherwise stated all reagents and chemicals were purchased from Sigma-
Aldrich or Fisher Scientific. Palmitoyl Coenzyme A was purchased from Avanti 
Polar lipids. All primers were purchased from Sigma-Aldrich. Competent cells were 
purchased from either Novagen, Invitrogen or New England Biolabs (Table 3-1). All 
chromatography columns and equipment were purchased from GE Healthcare or 
Qiagen. 
 
Myriocin is a poorly soluble compound even in 100% DMSO, with the highest 
possible concentration being only 5 mM and is only acheivable when the sample is 
heated to 80oC to aid solvation. Upon cooling to less than 5 oC myriocin would 
precipitate from DMSO and required further heating to re-dissolve. Therefore 
myriocin solution cannot be stored conveniently at either 4 oC or -20 oC until use. 
When adding myriocin stock solution to assays care must be taken not to add 
myriocin directly to cold buffers as this can also cause precipitation thus introducing 
inaccuracies into assays as well as problematic background absorbance in UV-vis 
experiments.  
 
The pET28a-N-terminalHis-spSPT plasmid had already been constructed in house by 
Beverley Yard and Dominic Campopiano.100 
 
3.1.1.1 Competent E. coli Cell Lines  
Species Cell Line Application Volume
E. coli BL21 DE3 (Novagen) Transformation and protein expression 10 µL 
E. coli DH5α (Invitrogen) Transformation and plasmid storage 25 µL 
E. coli HMS 174 DE3 
(Novagen) 
Transformation and protein expression 25 µL 
E. coli C2987 (NEB) Transformation of ligations and 
mutagenesis products 
15 µL 
Table 3-1 Competent Cells 
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3.1.1.2 Cell Stocks 
DNA was transformed into the appropriate cell line (depending upon end usage) and 
plated onto LB agar and grown overnight at 37 oC. One colony was used to inoculate 
LB (5 mL). The culture was grown overnight at 37 oC with agitation. Glycerol (20 % 
v/v) was added and cells were frozen at -80 oC until required.  
 
3.1.1.3 Sterile Conditions 
All media, agar, pipette tips, eppendorfs and flasks were sterilised prior to use. 
Sterilisation was performed in a LTE® touchclave lab autoclave at 120 oC, 1 atm for 
20 minutes. All manipulations of cultured cells were performed in close vicinity to a 
lit Bunsen burner to help create a sterile environment. 
 
3.1.1.4 Growth Media 
All media was dissolved in water that had been deionised, 0.22 µm filtered and UV 
treated before the final pH was adjusted to 7.5 using either hydrochloric acid (conc) 
or sodium hydroxide (5 M). The media was then autoclaved and either used that day 
or stored at 4 oC for a maximum of 4 days.  
 
Formulations 
2YT tryptone (16 g L-1), yeast extract (10g L-1) and sodium 
chloride (5 g L-1) 
LB 
(Lysogeny broth) 
tryptone  (10 g L-1), yeast extract (5 g L-1) and sodium 
chloride (10 g L-1) 
SOC 
(Super Optimal broth 
with Catabolite 
repression) 
tryptone (20 g L-1), yeast extract (5 g L-1), sodium chloride 
(0.58 g L-1), potassium chloride (1 M, 2.5 mL), magnesium 
chloride (1 M, 10 mL), magnesium sulfate (1 M, 10 mL) 
and glucose (1 M, 20 mL) 
Terrific  tryptone (12 g L-1), yeast extract (24 g L-1), glycerol (4 mL), 
potassium phosphate (2.31 g L-1) and di-potassium 
phosphate (12.54 g L-1) 
Table 3-2 Media Formulations 
 
3.1.1.5 Agar 
LB-Agar was purchased from Sigma-Aldrich and dissolved in purified water before 
being autoclaved. The appropriate antibiotic was added only when the agar had 
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cooled to less than 50 oC. Plates were poured and allowed to set before being stored 
at 4 oC for up to 1 week before use. 
 
3.1.1.6 Antibiotic Solutions 
Antibiotic stock solutions were made with deionsied, 0.22 µm filtered and UV 
treated water. Kanamycin 30 mg/mL stock solution was made and stored at 4 oC until 




All buffers were made by dissolving the appropriate reagents in deionised, 0.22 µm 
filitered and UV treated water and adjusted, if required, to the correct pH using either 
conc HCl or 5 M NaOH. Buffers used for chromatography were 0.22 µm filtered 
again, and degassed before use. Buffers were stored for up to 2 weeks at 4 oC. 
 
Abbreviation Components 
Stock Buffer 0.2 M potassium phosphate (KPhos), pH 7.5  (3.84 g L-1 potassium 
phosphate , 45.07 g L-1 di-potassium phosphate 
Buffer A 20 mM KPhos, pH 7.5, 150 mM NaCl, 25 µM PLP, 10 mM imidazole 
Buffer B 20 mM KPhos, pH 7.5, 150 mM NaCl, 25 µM PLP, 50 mM imidazole 
Buffer C 20 mM KPhos, pH 7.5, 150 mM NaCl, 25 µM PLP, 100 mM imidazole 
Buffer D 20 mM KPhos, pH 7.5, 150 mM NaCl, 25 µM PLP, 150 mM imidazole 
Buffer E 20 mM KPhos, pH 7.5, 150 mM NaCl, 25 µM PLP, 300 mM imidazole 
Buffer F 20 mM Tris pH 7.5, 150 mM NaCl and 25 µM PLP 
Buffer G 20 mM KPhos pH 7.5, 150 mM NaCl and 25 µM PLP 
Table 3-3 Buffers 
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3.2 Methods 
 DNA Manipulation 
3.2.1.1 Primers 
Name 5’-3’ Sequence 
spSPT H159C Forward ACAGCTGTGCGTCGATCTATGAC 
spSPT H159C Reverse ACGCACAGCTGTCGGCG 
spSPT Nco1 Forward ATATACCATGGCCGAAGCCG 
spSPT Nco1 Reverse TTCGGCCATGGTATATCTCCTT 
spSPT HIS TEV STOP 
Forward 
ATGGGCTGAGAGCACCACCAC 
spSPT HIS TEV STOP Reverse GTGCTCTCAGCCGATGACG 
 spSPT HIS TEV PLASMID 
STOP Forward 
ACTCGAGTGACACCACCACCACC 
 spSPT HIS TEV PLASMID 
STOP Reverse 
TGGTGGTGTCACTCGAGTGC 
AmSPT K286A Forward 
GTCGGCACTTTCTCTGCGTCTGTTGGAACT 
GTTGGC 
AmSPT K286A Reverse 
ACCCGCCAACAGTTCCAACAGACGCAGAG 
AAAGTGCCGAC 
AmSPT 19AA Truncation 
Forward 
CCCGACATCGCCATGGCACGCGACGTGCTC
AmSPT 19AA Truncation 
Reverse (pET Reverse) 
CTAGTTATTGCTCAGCGGT 
Table 3-4 Primers 
 
SDM primers were designed using the Liu method,152 which uses primers 
incorporating 3overhangs resulting in amplified DNA that is not nicked thus 
allowing newly synthesised DNA to be used as a template in subsequent rounds of 
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amplification. This simple alteration to existing SDM protocols results in SDM 
reactions becoming chain reactions which ultimately leads to less template DNA 
being required and thus making complete Dpn1 digestion easier. 
3.2.1.2 Transformation of competent E. coli  
Cells were removed from the -80 oC freezer and allowed to thaw. Once thawed, 
plasmid DNA (2 µL) was added to the aliquot and allowed to incubate for 20 
minutes. Cells were then heat-shocked for 40 seconds at 42 oC before cooling on ice. 
SOC media (80 µL) was immediately added and the cells were left shaking at 37 oC. 
After at least 1 hour, the cells were spread onto an LB kanamycin (30 µg mL-1) plate 
and left to grow overnight at 37 oC. 
 
3.2.1.3 Polymerase Chain Reaction (PCR): Site directed mutagenesis 
Each reaction contained forward primer (125 ng), reverse primer (125 ng), reaction 
buffer (5 µL, x 10 buffer), deoxynucleotide triphosphates (100 µM), template DNA 
(100 ng), Pfu Turbo DNA polymerase (2.5 U, 1 µL) with the reaction volume being 
adjusted to 50 µL with sterile water. 
 
The PCR reaction consisted of one initial 1 minute denaturation at 95 oC, followed 
by 18 cycles of 95 oC for 30 seconds, annealing at 57 oC for 1 minute and extension 
at 68 oC for 12.5 minutes. The reaction finished with one final 10 minutes 68 oC 
extension and then the sample was held at 4 oC and used within 24 hours. 
 
The PCR reaction mixture was then cut with the restriction enzyme DPN1 (10 U, 1 
µL) to remove any methylated template DNA. The restriction digest was carried out 
at 37 oC for greater than 1 hour.  The product was used to transform C2987 cells as 
mentioned in Table 3-1.  
 
3.2.1.4 PCR: Taq Polymerase Beads (GE Healthcare) 
To each Taq bead forward primer (125 ng), reverse primer (125 ng), DNA template 
(50 ng) and enough sterile water to make the volume up to 25 µL were added.  
The PCR reaction consisted of 30 cycles each containing a 95 oC denaturation for 1 
minute, a 55 oC annealing for 1 minute and a 72 oC extension for 2 minutes. An 
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additional 72 oC extension for 10 minutes was also added at the end. PCR products 
were stored at 4 oC and used within 24 hours. 
The PCR reaction mixture was then cut with the restriction enzyme DPN1 (10 U, 1 
µL) to remove any methylated template DNA. The restriction digest was carried out 
at 37 oC for greater than 1 hour. The product was then analysed by gel 
electrophoresis.    
3.2.1.5 Ligation into an Expression Vector 
Restricted plasmid (50 ng), insert DNA (3 times the number of moles of plasmid), 
buffer (5 µL 2x buffer), T4 ligase (3 U, 1 µL) and sterile water to make the volume 
of the reaction mixture up to 10 µL. Ligation reactions were left overnight at 4 oC.  
 
The product was used to transform C2987 cells as mentioned in Table 3-1. 
 
3.2.1.6 Digestion by Restriction Endonuclease 
A typical double restriction digest contained template DNA (40 µL), restriction 
buffer (4 µL, 10x buffer from New England Biolabs) and restriction enzymes (2 µL). 
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 DNA Purification 
3.2.2.1 Purification of DNA from cells: Qiagen Spin Miniprep Kit 
An overnight culture (5 mL) was centrifuged to give a cell pellet (1100 g for 10 
minutes). The supernatant broth was then discarded and DNA extracted following 
the manufacturer’s instructions.  The cell pellet was resuspended in 250 µL buffer P1 
(50 mM Tris-HCl, pH 8.0, 10 mM EDTA and 100 µg mL-1 RNAse A) and 
transferred to an eppendorf tube. The cells were lysed by alkaline lysis by the 
addition of 250 µL buffer P2 (200 mM NaOH and 1% SDS). The tube inverted 
several times, before the addition of 350 µL of neutralisation buffer N3 (4.2 M 
GuHCl, 0.9 M KOAc, pH 4.8), which was immediately followed by vigorous 
mixing. The resulting suspension was centrifuged (11000 g for 10 minutes) 
following which the supernatant was transferred to a QIAprep™ spin column and 
centrifuged (11000 g for 1 minute). The flow through was discarded, and the column 
washed with 750 µL of buffer PE (10 mM Tris, pH 7.5, 80% ethanol) and 
centrifuged (11000 g for 1 minute). The supernatant was discarded and the column 
was centrifuged (11000 g for 1 minute) again to remove any residual buffer. The 
DNA was then eluted with sterile water (70 µL) into a sterile eppendorf tube and 
stored at -20 oC until required. 
3.2.2.2 Extraction of DNA from Agarose gel: Qiagen Gel Extraction Kit  
DNA in agarose gel (1%) was visualised using UV light (254 nm) and the 
appropriate portion of the gel was removed and DNA extracted following the 
manufacturer’s instructions.  Agarose containing DNA was covered with the minimal 
volume of buffer QG (usually about 300 µL, 20 mM Tris HCl pH 6.6 and 5.5 M 
guanidine thiocyanate) and incubated at 50 oC until all the agarose gel had dissolved. 
The solution was transferred to a spin column, and centrifuged (11000 g for 1 
minute). The flow through was discarded, and the column was washed with more 
buffer QG (500 µL) and centrifuged (11000 g for 1 minute). The flow through was 
again discarded, and the column washed with 750 µL of buffer PE (10 mM Tris, pH 
7.5, 80% ethanol) and centrifuged (11000 g for 1 minute). The flow through was 
again discarded, and the column centrifuged (11000 g for 1 minute) to remove any 
residual buffer.  The DNA was eluted into an eppendorf tube with sterile water, (15 
µL) and stored at -20 oC until required. 
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 DNA Analysis 
3.2.3.1 Digestion by Restriction Endonuclease 
A typical single restriction digest contained template DNA (8 µL), restriction buffer 
(1 µL, 10x buffer from New England Biolabs) and restriction enzyme (1 µL). The 
mixture was incubated at 37 oC for more than 1 hour before being analysed by 
electrophoresis. 
3.2.3.2 Horizontal Electrophoresis 
Agarose (1 g) was added to TAE buffer (100 mL, Qiagen) and heated until all the 
agarose was in solution. Once the solution had cooled to less than 50 oC, either 
ethidium bromide (10 µL, 10 mg mL-1) or GelRed™(10 µL, Biotium) where added.  
After mixing the solution was poured in the casting mould and allowed to set at room 
temperature. DNA loading dye (5 × buffer, Bioline) was added to each sample. The 
gel was submerged in TAE buffer, samples loaded and the gel was run at a constant 
voltage (100 V) until good separation was achieved between all bands. 
3.2.3.3 Sequencing PCR 
To the DNA sample (3 µL) that required sequencing, sequencing buffer (2 µL, 5 x, 
Applied Biosceince), Big Dye™ version 3.1 (2 µL) and either forward or reverse 
sequencing primer (1 µL, 10 µM stock). All primers were purchased from Sigma-
Aldrich. The sequencing programme consisted of 25 cycles of 95 oC for 30 seconds, 
50 oC for 30 seconds and 60 oC for 4 minutes. 
Primer Name 5’-3’ Sequence 
pET Forward TTAATACGACTCACTATAGGG 
pET Reverse CTAGTTATTGCTCAGCGGT 
pGem Forward TAATACGACTCACTATAGGG 
pGem Reverse ATTTAGGTGACACTATAGAA 
Table 3-5 Sequencing Primers 
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 Protein Purification and Isolation 
3.2.4.1 Large Scale Over-Expression in E. coli 
One colony was used to inoculate LB broth (500 mL) containing kanamycin (30 µg 
mL-1) and was allowed to grow overnight at 37 oC with shaking (250 rpm). The 
inoculant was divided into LB broth (9 x 500 mL) containing kanamycin (30 µg mL-
1) and grown to an OD600 of 0.6 at 37 oC before protein expression was induced with 
IPTG (0.1 mM). Protein was expressed for 5 hours at 30 oC. Cells were harvested by 
centrifugation (7277 g, 10 minutes). Cells were stored at -20 oC until required. 
 
3.2.4.2 Cell Lysis – Sonication 
All manipulations of cells were performed on ice. The cell pellet was resuspended in 
buffer A (6:1 v/w ratio, also containing protease inhibitor cocktail (Roche)) and 
sonicated for 10 cycles (30 seconds on, 30 seconds off) using a Soniprep 150. 
Sample was kept on ice during the sonication process to counteract heat generated by 
sonication. Cell debris was separated by centrifugation (47000 g, 30 minutes at 4 oC). 
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 Protein Purification 
3.2.5.1 Purification of S. paucimobilis SPT 
Ni-NTA Agarose Affinity Chromatography 
The CFE was filtered (0.22 µm) and incubated with Ni-NTA agarose resin (2 mL, 
Qiagen) at 4 oC for 1 hour. Nickel resin was centrifuged (11000 g, 1 minute) prior to 
use to remove excess ethanol. After incubation the slurry was poured into an empty 
polypropylene column (5 mL) and allowed to pack under gravity. The column was 
washed with buffer A (40 mL) and protein eluted with buffer B, C, D and E (20 mL 
of each).  
 
Qiagen resin regeneration 
Previously used resin was washed and stored in 20% ethanol until it was recycled 
following the “quick protocol” outlined by Qiagen. This involved a 30 minute wash 
with 0.5 M NaOH, thorough rinsing with water to remove any excess NaOH and 
storage in 20 % ethanol at 4 oC for up to two months. If cleaned correctly and stored 
in the fridge in 20% ethanol regenerated resin could be used for 4 times before poor 
protein binding was observed.   
 
Size Exclusion Chromatography 
A HiPrepTM 16/60 SuperdexTM S-200 High Resolution size exclusion column was 
equilibrated with 1 column volume of buffer F (120 mL). The protein sample was 
concentrated (5 mL) and loaded on to the column. The protein was eluted with 1 
column volume of buffer F which was collected in 5 mL fractions. The molecular 




Equation 3-1 Equations required to convert elution volume to predicted molecular weight  
Kav = proportion of pores available to the protein. MW is plotted against Kav and the equation of the 

















   52
 Protein Analysis 
3.2.6.1 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
A typical gel (6 mL) consisted of a 4 mL 15 % running gel (2.185 mL H2O, 5 mL 
acrylamide (30 %), 2.5 mL TRIS 1.5 M pH 8.8, 100 µL 10 % w/v SDS, 200 µL 
ammonium peroxodisulfide 50 mg mL-1 and 15 µL TEMED) and 2 mL 4 % stacking 
gel (5.8 mL H2O, 1.35 mL acrylamide (30 %), 2.5 mL TRIS 0.5 M pH 6.8, 100 µL 
10 % w/v  SDS, 200 µL ammonium peroxodisulfide 50 mg mL-1, 15 µL TEMED). 
All protein samples were denatured by the addition of SDS loading buffer (3 mL Tris 
1.5 M pH 8.8, 5 % v/v glycerol, 10 % w/v SDS, 0.4 mL β-mercaptoethanol and 0.05 
% w/v bromophenol blue) and boiled for 10 minutes. The mixture was centrifuged 
(11000 g, 1 minute) before sample was loaded on to the gel. Molecular weight 
marker (10 µL, Low Molecular Weight Marker, GE Healthcare) was also loaded. 
The gel was run for 50 minutes at a constant voltage of 200 volts. The protein was 
visualised by staining with Coomassie stain (H2O, 0.1 % w/v Coomassie brilliant 
blue R250, 40 % v/v methanol and 10 % v/v acetic acid) and incubated for 20 
minutes at 37 oC. The gel was destained (H2O, 40 % v/v methanol and 10 % v/v 
acetic acid) until excess blue was removed.  
3.2.6.2 Bicinchoninic acid (BCA) Protein Assay 
This assay relies on reduction of Cu2+ to Cu+ by peptide bonds in the protein in an 
alkaline environment (Figure 3-1).153  
 
Figure 3-1 Reduction of cupric by the peptide bonds present in protein  
 
The Cu+ is then detected by the bicinchoninic acid (Figure 3-2) in a 2:1 ratio. The 
binding of Cu+ causes a colour change from green to purple and can be detected by a 
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Figure 3-2 Bicinchonic Acid 
 
The protein sample (50 µL) was added to the working solution (1 mL, 50:1 solution 
A:solution B) and incubated for 30 minutes at 37 oC. A standard curve was produced 
from serial dilutions (2. 1.5, 1, 0.75, 0.5, 0.25, 0.125, 0.025 and 0 mg mL-1) of a 
known stock of BSA. The absorbance of the sample was then taken and the 
concentration calculated from the standards.   
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 Protein Chemistry 
3.2.7.1 Spectroscopic Measurements 
All UV-vis spectra were recorded on a Varians Cary 50 UV-Vis spectrophotometer 
and analysed using Cary WinUV software (Varian). To ensure SPT was in the holo 
form the enzyme was dialysed overnight at 4 oC against buffer G. Excess PLP was 
removed by passing the protein through a PD-10 desalting column (SephadexTM G-
25 medium, GE Healthcare) before any spectrophotometry was under taken. The 
spectrophotometer was blanked with 20 mM KPhos (pH 7.5) containing 150 mM 
NaCl. 
3.2.7.2 5,5'-dithiobis-2-nitrobenzoic acid (DTNB) Assay 
SPT activity was measured using a continuous spectrophotometric assay by 
monitoring the release of CoASH from palmitoyl-CoA. The principle of the assay is 
that the free thiol on the CoA will react with 5,5'-dithiobis-2-nitrobenzoic acid 
breaking the disulfide bond and making the coloured TNB- anion                       



























Figure 3-3 DTNB Assay 
 
The production of TNB- can be monitored by an increase in the absorbance at 412 
nm. A typical experiment was carried out in a 0.5 mL plastic cuvette and contained 
SPT (50 µL, 2 µM), L-Serine (50 µL, 200 mM), DTNB (250 µL, 0.4 mM in 5 mM 
sodium acetate and 100 mM HEPES pH 8) and H2O (100 µL). The absorbance at 
412 nm was monitored for 1 minute to check for any background absorbance before 
the addition of palmitoyl-CoA (50 µL, 2.5 mM). Absorbance was monitored for 
another 14 minutes. L-Serine concentrations were varied from 0.1 mM – 40 mM. 
Kinetic constants (kcat and Km) were calculated from Michaelis-Menten plots using 
Sigma Plot. 
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3.2.7.3 Determination of dissociation constants for substrates and 
product quinonoid 
Binding assays typically contained 20 µM enzyme in 20 mM KPhos (pH 7.5). 
Varying amounts of L-serine (0-40 mM) were added and after addition of the 
substrate, the reaction mixture was allowed to equilibrate for 15 min at 25 °C. The 
Kd values were calculated from plots of ∆425 versus L-serine concentrations by fitting 




Equation 3-2 Equation for calculating Kd 
∆Aobs represents the observed change in absorbance at 425 nm, ∆Amax is the maximal absorbance 
change, [serine] represents L-serine concentration, and the Kd is the dissociation constant. 
 
To form the substrate quinonoid, 40 mM L-serine and 1.5 mM S-(2-oxoheptadecyl)-
CoA were added to the enzyme. After addition, the reactants were mixed and 
allowed to equilibrate for 15 min at 25 °C. To form the product quinonoid, 25 µM 
KDS was added to the enzyme and allowed to equilibrate for 15 min at 25 °C. 
 
3.2.7.4 Hexadecanal Assay 
Activity was quantified by monitoring the reaction of the co-product CoASH with 
DTNB. The reaction was performed on a 250 μL scale, SPT (200 nM) was incubated 
with L-serine (20 mM) in the presence of varying hexadecanal concentrations (20, 
40, 80, 125, 250, 500 and 1000 μM). The reaction was started by the addition of the 
second substrate palmitoyl-CoA (250 μM). A typical experiment contained 200 nM 
SPT, 20 mM L-serine, 250 μM palmitoyl-CoA, hexadecanal and 0.2 mM DTNB in 
100 mM Hepes, pH 8.0. An IC50 value of 144 ± 17 μM was calculated using 




Kd + [serine] 
=
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3.2.7.5 Mass Spectrometry 
Liquid Chromatography Fourier Transform Ion Cylotron Resonance Mass 
Spectrometry (LC-FT-ICR) 
On-line liquid chromatography was performed using an Ultimate 3000 HPLC system 
(Dionex) equipped with a monolithic PS-DVB (500 μm × 50 mm) reverse-phase 
analytical column (Dionex) coupled to electrospray ionisation (nESI). Protein digests 
(5 pmoles) were loaded onto the column (maintained at 60°C) followed by a 30 min 
linear gradient from 2 to 70% acetonitrile (flow rate 20 μl/min). All mass spectra 
were recorded on SolariX FT-ICR mass spectrometer equipped with a 12 Tesla 
superconducting magnet (Bruker Daltonics). Transient data size was set to 1 M word 
for each acquisition.  
 
Native mass spectrometry 
Data was acquired on a SolariX FT-ICR mass spectrometer, as described above. 
Samples, typically 2 µM, were treated with 0.5% para-nitrobenzoic acid prior to 
analysis; and ESI ionisation was employed using a syringe pump operating at a flow 
of 500 µl h-1. RF frequencies used in all ion-transmission regions were the lowest 
available value: multipole 1 (2 MHz), quadrupole (1.4 MHz) and transfer line (1 
MHz). Ion-funnel and skimmer voltages were 200 V (funnel 1), 130 V (skimmer 1), 
8 V (funnel 2) and 3V (skimmer 2). The collision voltage for the collision cell was 
varied between 10 and 20 V, to produce optimal signal. Ions were accumulated for 
400 ms in the RF-hexapole ion trap before being transmitted to the infinity ICR trap 
and detected between m/z 1000 and 5000 to yield a broadband 1 M time-domain 
transient. Typically, each spectrum was the sum of 100 mass analyses. Mass spectra 
were externally calibrated using ES tuning mix (Agilent). The resulting spectra were 
analysed using DataAnalysis software (Bruker Daltonics); spectra were smoothed 
using the Gaussian algorithm and a smooth width of 0.15 m/z, before maximum 
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Online Tandem Mass Spectrometry  
Online tandem mass spectrometry (MS) was performed on the SolariX FT-ICR 
Instrument. After the initial LC-MS run specific peptides of interest were selected for 
fragmentation. The protein digest was separated using an identical gradient to the 
above. However, the mass resolving quadrupole was set to select for a specific m/z 
throughout the LC-MS run and MS/MS was performed using collision-induced 
dissociation (CID). All spectra were externally calibrated using ES tuning mix 
(Agilent Technologies) and analyzed using DataAnalysis software (Bruker 
Daltonics), as above. For analysis of the tryptic digest, the SNAP 2.0 algorithm was 
used for automated peak picking in order to create a list of peptide masses. For CID 
experiments, fragment lists were created (using SNAP 2.0) and the resulting mass 
lists were searched against the relevant primary sequences using Prosight PTM 
software. Error tolerances were set to 10ppm. Isotope distributions of specific charge 
states were predicted from theoretical empirical formulae. These were overlaid upon 
the recorded experimental data as scatter plots. 
 
3.2.7.6 Structural Biology 
Proteins were screened for suitable crystallisation conditions in St Andrews in 
collaboration with Dr Stephen McMahon in the laboratory of Professor Jim 
Naismith. All proteins underwent both Ni affinity and size-exclusion 
chromatography (column eluted with 10 mM Tris, 150 mM NaCl and 25 µL PLP to 
avoid KPhos which readily crystallises). Protein was then concentrated to                
20 mg mL-1 and the screens built on a Hamilton Microstar liquid handling robot 
controlled by the Rhombix system software (Thermo). Crystallisation trials were set 
up as a 1+1 (150 nL Protein and 150 nL well solution) and 2+1 (300 nL Protein and 
150 nL well solution) sitting drops. Plates were immediately sealed and left for up to 
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K265A SPT:PLP-myriocin external aldimine inhibitor complex – PDB code 
4BMK 
Protein for crystallisation was concentrated to 20 mg mL−1 and incubated with 5 
equivalents of myriocin immediately prior to crystallisation trials. Crystals of K265A 
SPT were grown by vapour drop diffusion at 20 °C over the course of 2 weeks and 
are readily reproducible. The optimum growth conditions are 32% PEG MME 2000, 
0.1 M HEPES pH 7.5, and a protein:precipitant ratio of 1:1. Prior to data collection 
the crystals were cryo-cooled in mother liquor doped with 20% glycerol. Data were 
collected at Beamline I04-1 at the Diamond Synchrotron Light Source, Oxfordshire, 
England, and processed in an automated manner using Xia2.154 The structure was 
solved by molecular replacement using PHASER155 and PDB code 2JG2 as a model. 
The myriocin dictionary was created using PRODRG.156 The model was refined 
using REFMAC5157 with TLS. COOT158 was used for manual manipulation of the 
structure and model quality was assessed throughout with MOLPROBITY.159 Data 
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4 Results and Discussion 
4.1 SPT Variants 
The first identification, isolation and cloning of Sphingomonas paucimobilis SPT 
was accomplished by Ikushiro et al. in 200199 (DNA and protein sequences are 
shown in Appendix 1). This cloning by Ikushiro allowed the Campopiano lab to 
generate recombinant spSPT from genomic Sphingomonas paucimobilis DNA in 
2006100 (see also Yard B.A. PhD Thesis). The resulting DNA sequence was cloned 
into a pET-28a vector and named pET-28a SPT. Subsequent lab members later re-
cloned pET-28a SPT to encode for a C-terminal histidine tag in preference over the 
original N-terminal tag, for purification purposes, henceforth that protein is referred 
to as spSPT (DNA and protein sequences are shown in Appendix 1). This 
recombinant spSPT form matches the published sequences exactly but also contains 
an extra eight amino acids; leucine, glutamic acid and six histidines at the C-
terminus. 
 
 Purification, characterisation and activity of spSPT 
Plasmid pET 28a spSPT was used to transform BL21 (DE3) cells which were in turn 
used to express spSPT in LB with 0.1 mM IPTG for 5 hours at 30 oC. The protein 
was isolated from the CFE by gravity flow nickel affinity chromatography using 
nickel resin (Ni-NTA Agarose – Qiagen) followed by a stepwise imidazole gradient 




Figure 4-1 Optimised purification of spSPT 
Left - Lane 1: Low molecular weight marker, Lane 2: Supernatant, Lane 3: Pellet, Lane 4: Flow 
through, Lane 5: Wash 1 - 30 mM Imidazole wash, Lane 6: Wash 2 - 30 mM Imidazole, Lane 7: 
Elution 1 - 300 mM Imidazole, Lane 8: Elution 2 – 300 mM Imidazole. Right - Elution profile from 
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Size exclusion chromatography revealed that spSPT behaved as a single species in 
solution with a mass of roughly 92 kDa, corresponding to the formation of a 
homodimer (Figure 4-1 Right). 
 
Purified protein was routinely analysed by LC-ESI MS to confirm purity and assure 
reproducibility. The predicted mass of apo spSPT is 46104 Da and would also be the 
expected observable species under LC-MS conditions. The labile nature of the imine 
bond between the active site lysine and PLP in the internal aldimine conformation, 
results in the loss of PLP in normal mass spectrometry conditions. The 
experimentally observed mass was 45975 Da, demonstrating spSPT had lost its N-
terminal methionine after translation (Figure 4-2). A relatively common post-
translational modification in recombinant proteins expressed in E. coli.  
Figure 4-2 Intact protein mass spectrometry of spSPT 
Deconvoluted intact protein mass spectrum of spSPT (40 M) 
with an average neutral mass of 45975 Da. 
 
Following purification the protein could then be stored for long periods of time 
frozen at -80 oC, once mixed with 20% glycerol the protein was rapidly cooled in 
liquid nitrogen before being transferred to the freezer. When required the protein was 
removed from the freezer, thawed on ice and dialysed against a fresh PLP buffer 
(buffer G in Table 3-3). Both mass spectrometry and enzymatic assays showed no 
deterioration in the protein following up to 6 months in the freezer.  
 
At all points throughout the purification the presence of PLP can be observed due to 
its distinct yellow colour which is faintly visible in the E. coli cell pellet, more 
45975 Da (av) 
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distinctly in the supernatant and unmistakable in the affinity column elution fraction 








Figure 4-3 Characteristic colour of PLP containing solutions 
Left – 750 L aliquot of the supernatant generated after lysis of spSPT producing E. coli cells.  
Right – 750 L aliquot of the elution fraction generated from the Nickle affinity purification step of 
spSPT. 
 
Before all UV-vis experiments excess PLP was removed by passing the sample 
through a PD-10 desalting column (Sephadex G-25M, GE Healthcare). UV-vis 
spectroscopy showed that PLP was bound to the enzyme and existed in the expected 
two tautomeric forms (Figure 4-4 Top and Bottom Left). 
 
Figure 4-4 UV-vis spectrum and kinetic analysis of spSPT 
Top – The two visible, tautomeric, forms of PLP when it is bound to SPT in the internal aldimine 
conformation. Bottom left - The black line shows the holo-form of the enzyme (40 M SPT, 20 mM 
KPhos buffer (pH 7.5), 150 mM NaCl, 25 °C). Increasing concentrations of L-serine were added (0.1, 
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Addition of L-serine to the enzyme altered the PLP equilibrium as expected, 
producing more of the ketoenamine form of PLP.29 The titration of increasing 
amounts of L-serine (0.1, 0.5, 1, 5, 20, 40 and 50 mM) to the enzyme produces a 
successively larger 425 nm absorbance which can be used to calculate the 
dissociation constant (Kd) for L-serine, 1.4 ± 0.1 mM (Figure 4-4 Bottom Right). 
Alternatively substrate concentrations can be varied in rate assays, with the resulting 
changes in rate plotted in the typical Michaelis-Menten manner to produce a 
Michaelis constant (Km) for L-serine of 1.5 ± 0.1 mM (Figure 4-5).  
 
Figure 4-5 The effect of changing L-serine on initial reaction rate 
Kinetic analysis of spSPT using the DTNB assay. Initial rates of CoASH release measured 
spectrophotometrically at 412 nm and at several final concentrations of L-serine (0.1, 0.5, 1, 5, 10 and 
20 mM) Each assay contained 700 nM enzyme, 250 M palmitoyl-CoA, 0.2 mM DTNB and the 
appropriate L-serine standard. 
 
Although spSPT had previously been purified in our lab, improvements upon 
repetition were made. Purification was completed successfully at room temperature, 
rather than at 4 oC for the first time with no deleterious effects upon enzyme activity 
or UV-vis spectroscopy, although the enzyme was always stored at 4 oC if it was not 
required immediately. The optimal nickel affinity chromatography conditions were 
determined for Qiagen resin. Two 30 mL washes (30 mM imidazole) followed by a 5 
mL elution (300 mM imidazole). Nickel affinity chromatography has been shown to 
work equally as well with both new and recycled resin.  
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 Purification, characterisation and activity of AmSPT 
Initial work focussed on re-establishing the ability to grow diffraction quality crystals 
of spSPT following the success of previous group members, especially Dr. Marine 
Raman.29 Unfortunately this goal was never reached. Despite fastidious attention to 
detail and accurate replication of the published method no adequately-sized, good 
quality spSPT crystals could be grown. After several failed crystal trials it became 
apparent that the ability to produce SPT crystals had actually been lost approximately 
9 months prior to me starting of my PhD. However initial trials started by trying to 
exactly replicate Dr. Raman’s published method. The use of the same construct, 
preparation procedure, columns and crystal screens all failed to yield any results. In 
an attempt to circumvent this roadblock other SPT constructs were considered. Our 
collaborator Professor Teresa Dunn (Uniformed Services University, Bethesda, 
U.S.A.) provided the group with a new, unpublished spSPT isoform, denoted 
AmSPT due to its American origin. This synthetic AmSPT gene had been codon 
optimised for Arabidopsis expression for another project but expression in E. coli 
was attempted (DNA and protein sequences are shown in Appendix 1). Due to the 
difficulties experienced in purifying N-terminally tagged SPT and the mobile nature 
of the N-terminus in crystal structures AmSPT has been engineered with a 12 amino 
acid linker between the start of the sequence and the N-terminal histidine tag (Figure 
4-6).  
 
Figure 4-6 pET28a plasmid map of AmSPT 
 
AmSPT was treated as a completely new protein and therefore underwent expression 
and purification screens before the optimal procedure was deduced. Protein 
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expression was initially attempted in both HMS174 (DE3) and BL21 (DE3) for 
various lengths of time under the control of numerous IPTG concentrations. Optimal 
expression was observed in BL21 (DE3) cells for 5 hours with only 0.1 mM IPTG 
required. Initial purification was undertaken at both room temperature and 4oC but no 
difference in UV-vis characteristics or enzyme rates were observed therefore all 
subsequent purifications were carried out at room temperature. Nickel affinity 
chromatography (Figure 4-7 Left) followed by size exclusion chromatography 
(Figure 4-7 Right) generated pure AmSPT as expected. AmSPT eluted from the gel 
filtration column in the predicted homodimeric state with an elution volume roughly 
corresponding to 92 kDa, similar to what was obtained with spSPT. 
 
Figure 4-7 Optimised purification of AmSPT 
Left - Lane 1: Low molecular weight marker, Lane 2: Supernatant, Lane 3: Pellet, Lane 4: Flow 
through, Lane 5: Wash 1 - 30 mM Imidazole wash, Lane 6: Wash 2 - 30 mM Imidazole, Lane 7: 
Elution 1 - 300 mM Imidazole, Lane 8: Elution 2 – 300 mM Imidazole. Right - Elution profile from 
Sephacryl16/60 S200 size exclusion column, red line showing absorbance at 280 nm.  
 
AmSPT was routinely analysed by mass spectrometry to monitor the effectiveness of 
individual protein preparations. The measured AmSPT apo mass of 47231 Da 
(Figure 4-8) matches the predicted mass (47363 Da) minus the initial methionine 
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Figure 4-8 Intact protein mass spectrometry of AmSPT 
Intact protein mass spectrometry of AmSPT (40 M) with an average neutral mass of 47231 Da.  
-N-6-gluconoylation is marked was an *. 
Consistently throughout mass analysis a minor contaminant of larger mass can be 
observed (asterisks in Figure 4-8) which was eventually determined to be -N-6-
gluconoylation of the histidine tag (Figure 4-9). 
 
 
Figure 4-9 Structure of the -N-6-gluconoylation product 
Showing the adduct attached to the N-terminal glycine which is characteristically linked to two serines 
and then the histidine tag. 
 
-N-6-gluconoylation is a relatively new post-translational modification coinciding 
with the new era of highly overexpressed, affinity purified proteins from E. coli and 
corresponds to a 178 Da increase in mass from the addition of a gluconic acid 
derivative to the histidine tag.160 
AmSPT exhibited the characteristic UV-vis spectrum expected from an SPT isoform, 
consisting of PLP in both the enolimine and ketoenamine forms with absorbance 
maxima at 333 and 420 nm respectively (Figure 4-10). Upon addition of L-serine the 
resultant PLP:L-serine aldimine demonstrated the same preference for the 
ketoenamine form as it does with spSPT. The difference in absorbance at 425 nm at a 
range of L-serine concentrations (0.1 – 250 mM) allows the estimation of the Kd for 
L-serine binding to be made, 13.8 ± 0.6 mM (Figure 4-10). The reason why L-serine 













47231 Da (av) 
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structural change in AmSPT is the 20 amino acid N-terminal extension it must be 
concluded that this extension must cause a small conformational change that prevents 
optimum PLP:L-serine aldimine binding. Interestingly in the original crystal 
structure of spSPT the first 21 amino acids are not well defined in the electron 
density map and so the structure of the N-terminus is not known (see below). 
 
Figure 4-10 UV-vis spectrum and kinetic analysis of AmSPT 
Left - The black line shows the holo-form of the enzyme (40 M SPT, 20 mM Kphos 
buffer (pH 7.5), 150 mM NaCl, 25 °C). Increasing concentrations of L-serine were added (0.1, 1, 2.5, 
5, 10, 20, 40, 80, 160 and 250 mM) coloured lines. Right - Analysis of L-serine binding to generate a 
Kd. 
 
Utilisation of the DTNB assay at multiple substrate concentrations produced a Km for 
both L-serine and palmitoyl CoA of 2.9 ± 0.2 mM and 95 ± 6 M respectively 
(Figure 4-11). The kinetic parameters agree reasonably well with the determined 
values for spSPT, demonstrating that the addition of the N-terminal extension has 
had only a minor effect on the catalytic capability of AmSPT. The N-terminal 
extension was originally predicted to affect the palmitoyl-CoA binding due to the 
long alkyl chain of palmitate being predicted to occupy a hydrophobic channel 
pointing towards the disordered N-termini. To some extent this hypothesis could be 
correct as the Km for palmitoyl-CoA has increased 3 fold in comparison to spSPT. 
  
 









Figure 4-11 Km determination for L-serine and palmitoyl-CoA with AmSPT  
Kinetic analysis of AmSPT using the DTNB assay. Initial rates of CoASH release measured 
spectrophotometrically at 412 nm and at several final concentrations of L-serine (0.1, 0.5, 1, 5, 10, 20 
and 40 mM) (Left) or palmitoyl-CoA (2, 5, 10, 20, 40, 60, 80, 120, 160, 250, 500, 1000 and 1500 M) 
Each assay contained 700 nM enzyme, 250 M palmitoyl-CoA or the appropriate standard, 0.2mM 
DTNB and 20 mM L-serine or the appropriate standard. All experiments were done in triplicate. 
Graphs are plotted as mean readings with ± 2SDs appearing as error bars, for points without error bars 
the range is covered within the circular mark. 
 
The rates of reaction catalysed by spSPT and AmSPT were compared directly again 
by utilisation of the DTNB assay. Comparison of the turnover number (kcat) showed 
AmSPT to be half the velocity of spSPT (Table 4-1). With both enzymes having the 
same amino acid sequence this was difficult to rationalise and must again be 
attributed to the long N-terminus of AmSPT undergoing conformational change 
during catalysis, perhaps slowing down product release. When the rate of AmSPT is 
compared to other isoforms from different bacterial strains the small variation with 
spSPT appears less significant. Both S.wittichii and Bacteroides fragilis SPT are 
more than 10 fold slower than spSPT but this variation should be expected due to the 
differences in amino acid sequences, S.wittichii and Bacteroides fragilis respectively 
have only 75% and 35% identity with spSPT. Interestingly myriocin does not inhibit 
all of the SPT isoforms equally (Tabel 4-1). Previously the inhibition of SPT by 
myriocin had been unquestioned but the comparison of natural bacterial isoforms of 
SPT shows a wide variation in myriocin potency.  
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Table 4-1 Rate and myriocin inhibition comparison of various SPT isoforms 
 
Taken together with Ikushiro’s work with SPTs from Sphingobacterium multivorum, 
Sphingobacterium spiritivorum and Bacteriovorax stolpii produces the most 
comprehensive kinetic comparison of bacterial SPTs to date (Table 4-2). 
 
 
Table 4-2 Comparison of turnover rates for bacterial SPTs161 
  
 It is assumed that the active sites of each SPT shares a high level of similarity in 
order to allow them all to bind the same L-serine and palmitoyl-CoA substrates but 
clearly nuances in natural variation decrease myriocin binding affinity. In Ikushiro’s 
pioneering early work she also demonstrated that spSPT could also accept glycine, 
alanine and to a lesser extent threonine as substrates as well as tolerating 1-2 carbon 
extensions and truncations to the acyl chain of CoA reasonably well.99 The data also 
raises the possibility that myriocin acts allosterically at a site of greater variation in 
the amino acid backbone. As the mode of myriocin inhibition or site of action was 





2 eq. of Myriocin 
Activity with 
5 eq. of Myriocin 
spSPT 1.27 ± 0.06 1 40% 31% 
AmSPT 0.63 ± 0.05 0.49 29% 2.3% 
Sphingomonas 
wittichii 
0.068 ± 0.007 0.053 29% 17% 
Bacteroides 
fragilis 
0.005 ± 0.0006 0.004 100% 100% 
Bacteria kcat (s-1) 
Sphingomonas paucimobilis 1.27 ± 0.06 
Sphingomonas wittichii 0.068 ± 0.007 
Bacteroides fragilis 0.005 ± 0.0006 
Sphingobacterium multivorum 0.47 ± 0.10 
Sphingobacterium spiritivorum 1.20 ± 0.03 
Bacteriovorax stolpii 2.55 ± 0.12 
 
   70
unknown at this point the data were used to confirm AmSPT as the most suitable 
SPT isoform to attempt myriocin-SPT co-crystal trials with. While investigating the 
effect of myriocin upon various SPT isoforms the concentration of myriocin needed 
to gain maximal inhibition was also elucidated. The use of 5 equivalents of myriocin, 
200 μM against 40 μM SPT provided almost 98% inhibition within 2 minutes of 
addition with no further inhibition seen with 10 equivalents (400 μM). 
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 21 spSPT truncation 
To date all the published spSPT crystal structures have lacked definition at the N-
terminus with the first 21 amino acids not appearing in any structure. The lack of the 
N-terminal region has been apportioned to flexibility within the first 21 amino acids 
allowing several possible configurations thus resulting in indistinct electron density 
upon diffraction. During the course of research within the group the ability to 
crystallise any form of SPT with any combination of ligands or inhibitors was lost 
(occurring between 2009-2010). Following the dogma that smaller molecules 
crystallise easier resulted in the hypothesis that truncation of the mobile N-terminus 
could aid crystallisation. Comparing spSPT to Sphingomonas wittichii SPT (Figure 
4-12) highlights the non-essential nature of the first 20 amino acids and guided the 
decision to truncate spSPT. 
 
Figure 4-12 Protein sequence alignment comparing Sphingomonas paucimobilis SPT and 
Sphingomonas wittichii SPT 
Key - * (asterisk) indicates positions which have a fully conserved residues, : (colon) indicates 
conservation between groups of strongly similar properties and . (full stop) indicates conservation 
between groups of weakly similar properties, red = small, blue = acidic, magenta = basic and green = 
Hydroxyl, sulfhydryl, amine or glycine. 
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Primers (Table 3-4) were designed to introduce a start codon into spSPT as part of an 
Nco1 site (CCATGG), resulting in the new protein beginning with a methionine and 
an alanine (DNA and protein sequences are shown in Appendix 1). PCR using Taq 
polymerase, ligation into pGEM followed by sequencing revealed three single base 
mismatches as well as the desired start codon. The first base change was a deliberate 
deviation from the original DNA sequence in favour of a more common codon and 
was therefore a silent mutation. The second base change resulted in an L5V mutation 
and was due to poor primer design. The third change corresponded to a L335Q 
mutation and was the result of using Taq polymerase, a relatively low fidelity 
polymerase in comparison to Pfu and others. The double L5V, L335Q 21 spSPT 
mutant was carried forward into protein studies with the knowledge that a wild-type 
21 spSPT would be required later if initial crystal trials were successful.  
Test expression showed optimal L5V L335Q 21 spSPT production with 0.1 mM 
IPTG over 5 hours at 30 oC. Normal purification yielded copious protein (Figure 4-
13 Left) but size exclusion chromatography revealed larger molecular weight protein 
aggregates were forming, indicating that the removal of the N-terminus had affected 
the stability of the homodimer (Figure 4-13 Right). 
 
Figure 4-13 Optimised purification of 21 spSPT 
Left - Lane 1: Low molecular weight marker, Lane 2: Pellet, Lane 3: Supernatant, Lane 4: Flow 
through, Lane 5: Wash 1 - 30 mM Imidazole wash, Lane 6: Wash 2 - 30 mM Imidazole, Lane 7: 
Elution 1 - 300 mM Imidazole, Lane 8: Elution 2 – 300 mM Imidazole. Right - Elution profile from 
Superdex 16/60 S200 size exclusion column, red line showing absorbance at 280 nm.  
 
Preliminary UV-vis analysis showed normal PLP binding with two equal peaks at 
325 nm and 415 nm when in a Tris buffer. Rate comparison of L5V L335Q 21 
spSPT showed the truncation displayed decreased enzyme activity 5 fold compared 
with WT spSPT; the kcat of L5V L335Q 21 spSPT was 0.21 s-1 in comparison to 
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under estimated as both extension of the N-terminus, in the case of AmSPT, and its 
truncation both influence the catalytic rate. The two amino acid substitutions listed 
above could also play a role in either the increase aggregation or the decrease in rate.  
 
Crystal trials with L5V L335Q 21 spSPT yielded no crystals when either set-up 
natively or in combination with L-serine, myriocin or the palmitoyl-CoA analogue 
using either in-house or commercial screens. As the 21 spSPT was specifically 
developed to produce crystals upon failure to crystallise no further characterisation or 
attempts to rectify the two unwanted mutations were made. 
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 K286A AmSPT 
In an attempt to stall the catalytic mechanism after the addition of palmitoyl-CoA 
and trap the resulting tertiary complex before product formation a catalytically 
comprised mutant was engineered. This catalytically-inactive SPT isoform was 
designed to aid the elucidation of the palmitoyl-CoA binding site. Analysis of the 
SPT catalytic mechanism shows Lys265 to be crucial, not only for initial PLP 
binding, but also for deprotonation of the PLP:L-serine external aldimine. Therefore 
this residue was selected for mutagenesis. After the addition of the N-terminal linker 
and six histidine tag the amino acid numbering changes slightly with the key residue 
Lys265 corresponding to Lys286 in AmSPT. Employing the Liu et al.152 method of 
site directed mutagenesis using over hanging primers (Table 3-4) yielded the correct 
mutation. Mutagenesis was checked by DNA sequencing and, after protein 
expression and purification, by mass spectrometry. 
Test expression studies showed good expression in the same conditions as the wild 
type protein, 0.1 mM IPTG at 30 oC for five hours. Purification by nickel affinity and 
size exclusion chromatography proceeded uneventfully and yielded pure protein 
(Figure 4-14).  
 
Figure 4-14 Optimised purification of K286A AmSPT 
Left - Lane 1: Low molecular weight marker, Lane 2: Pellet, Lane 3: Flow through, Lane 4: 
Supernatant, Lane 5: Wash 1 - 30 mM Imidazole wash, Lane 6: Wash 2 - 30 mM Imidazole, Lane 7: 
Elution 1 - 300 mM Imidazole, Lane 8: Elution 2 – 300 mM Imidazole. Right - Elution profile from 
Superdex 26/60 S200 size exclusion column, blue line showing absorbance at 280 nm.  
 
Following initial purification the integrity of the protein was confirmed by mass 
spectrometry, with the observed apo mass correlating exactly to the predicted mass 
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Figure 4-15 Intact protein mass spectrometry of K286A AmSPT 
Intact protein mass spectrometry of K286A AmSPT (40 M) with an average neutral mass of 47174  
 
UV-vis analysis of the purified mutant protein showed one dominant peak at 400 nm 
and a much smaller peak at 323 nm, in contrast to the much more even distribution 
seen with WT AmSPT (Figure 4-16). This suggests that the non-covalently bound 
PLP preferred the ketoenamine form and that the K286A mutation had impacted 
upon PLP binding and shifted the equilibrium away from the usually dual PLP 
species. Upon addition of L-serine to this form of the protein no change in the UV-
vis spectrum was observed suggesting that L-serine is not interacting with PLP 
presumably because the PLP cofactor is not bound in a favourable position. This 
result suggests that the internal aldimine (PLP:Lysine imine bond) is essential for the 
recognition of the amino acid substrate and subsequent formation of the external 
aldimine (PLP:Serine imine bond). Taken together these findings suggest that the 
removal of the active site lysine in AmSPT does not stop PLP binding but only limits 
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Figure 4-16 UV-Vis analysis of WT AmSPT and K286A AmSPT. 
UV-vis spectrum of 40 M AmSPT (red trace) and K286A AmSPT (black trace) after excess PLP has 
been removed.  
 
The inability to bind PLP correctly, interact with L-serine or deprotonate the 
resulting aldimine all contribute to K286A AmSPT having no catalytic activity. 
Variation in DTNB assay conditions including a 10 fold increase in enzyme 
concentration coupled with the increases in substrate concentrations persisted in 
showing no enzyme turnover. The complete inactivity of AmSPT through a single 
amino acid change without causing protein mis-folding allows substrate and inhibitor 
binding studies to be undertaken without catalytic turnover, thus hopefully allowing 
capture of enzyme-bound substrates and inhibitors. 
 
A note on AmSPT numbering 
The emergence of the N-terminally tagged AmSPT has produced a nomenclature 
complication when comparing AmSPT to spSPT. The additional 21 N-terminal 
amino acids found in AmSPT increase all subsequent residue numbers, therefore 
making a functional comparison of the same residue between isoforms more 
cumbersome and confusing. The widely published, well-known tetrad of PLP 
binding residues in spSPT (H159, D231, H234 and K265) becomes (H180, D252, 
H255 and K286) in AmSPT. In an attempt to minimise confusion within the 
literature the N-terminal tag of AmSPT has not been included in the numbering of 
AmSPT therefore the active site residues remain recognisable by retaining their 
previous numbering. The K286A AmSPT mutant described above therefore becomes 
the K265A mutant. For clarity all subsequent references to amino acids in AmSPT 
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4.2  Myriocin 
Following its discovery as an SPT inhibitor the fungal natural product myriocin 
quickly became an important and widely used molecule in sphingolipid research. The 
widespread use of myriocin arose from both its high selectivity and relative ease of 
availability, in comparison to other natural product SPT inhibitors, as it is now 
commercially available from Sigma Aldrich. Historically, myriocin could be isolated 
in relatively high yields with only the requirement for very limited purification. From 
a 5 L fermentation roughly 650 mg of myriocin could be obtained.144 Despite its 
extensive use, the mode of action of myriocin has remained unknown with the only 
published comment on the mode of inhibition being made by Hanada in 2003, who 
suggests that the amine group of myriocin could condense with the aldehyde of PLP 
to form an aldimine (Figure 4-17).41  
 
Figure 4-17 Possible formation of a PLP:myriocin external aldimine 
 
Starting from this hypothesis the initial aim of the project was to find evidence for 
the existence of the PLP:myriocin aldimine. Utilisation of the characteristic UV-vis 
absorption pattern of PLP and its derivatives allowed the binding of myriocin by SPT 
to be monitored. After the dialysis of fresh PLP into the enzyme excess PLP was 
removed from the sample by passing through a PD-10 (Sephadex G-25M - GE 
Healthcare) desalting column before UV-vis analysis showed PLP to be present in its 
two tautomeric forms (Figure 4-18 solid line). Upon addition of 5 equivalents of 
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this was also accompanied by a visible change in colour. The myriocin containing 
solution is a clear bright yellow in comparison to the much paler yellow enzyme 
control. The UV-vis spectrum indicates a change has taken place. The loss of the 333 
nm peak indicates the disappearance of the original PLP:SPT aldimine. While the 
concomitant increase at 430 nm suggests the synthesis of a new species, potentially 







Figure 4-18 UV-vis spectrum of AmSPT before and after myriocin addition  
40 M AmSPT before (solid line) and after 200 M myriocin addition (dotted line). 
 
Following on from the work above (Section 4.1.2) five equivalents of myriocin was 
used throughout all inhibition studies as this produced the maximum enzyme 
inhibition and largest aldimine formation based on the 430 nm absorbance. Due to its 
low solubility, myriocin was solubilised in DMSO at a maximum concentration of 5 
mM. Therefore myriocin concentrations were kept as low as possible to minimise 
any DMSO interference. Initial experiments assessed the enzyme activity in the 
presence of 1, 2.5, 5 and 10 equivalents of myriocin along with the appropriate 
DMSO controls. DMSO was shown to be tolerated up to 10% with only a very minor 
effect on enzyme rate. 98% inhibition of SPT was achieved when 5 equivalents of 
myriocin were added, with no greater inhibition observed with 10 equivalents. 
Throughout the UV-vis experiments precipitation was frequently observed if 
precautions were not taken. To minimise precipitation the inhibitor was only added 
when the enzyme solution had risen to room temperature. Although SPT was stored 
at 4 oC immediately prior to use the temperature of all UV-vis experiments was 
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To prove the existence of the hypothetical PLP:myriocin external aldimine further 
evidence of the structure was gathered. Initial attempts at structure verification 
centred around reducing the labile PLP:myriocin imine bond followed by mass 
spectrometry. The labile nature of the imine bond formed between the aldehyde of 
PLP and any amine has been well utilised during mechanistic studies and indeed 
forms the basis of PLP chemistry. PLP is initially held in the active site of SPT via 
an imine interaction, this interaction is then broken and replaced by a second imine 
bond upon L-serine addition. The well established field of reduction/oxidation 
chemistry has been used to aid SPT chemistry since its discovery.76 With the addition 
of the relatively strong reducing agent, sodium borohydride, directly to enzyme 
assays becoming a well established technique for trapping PLP-substrate 
intermediates.29, 34  
In this work, SPT that was treated with myriocin and the increase in absorbance at 
430 nm was confirmed before reduction by addition of 10 mM sodium borohydride. 
After reduction all protein was removed from the sample by passing through a 6 kDa 
molecular weight cut-off membrane before LC-MS analysis was attempted. The pre-
analytical chromatography consisted of a simple C18 reverse phase column. 
Surprisingly, no ions corresponding to the existence of a PLP:myriocin aldimine 
could be observed. Extensive repetition and subtle modifications to the procedure 
produced no results. Considering possible sources of error the removal of the protein 
by molecular weight filter membranes was stopped to eliminate any possibility of the 
imine being lost at this step. Repetition of the experiment without protein removal 
but direct loading onto the LC-MS still did not produce any viable product ions. 
Ultimately neither a reduction or protein removal steps were used to detect the 
PLP:myriocin aldimine. The chromatography gradient was altered to remove the acid 
modifier from the mobile phase in an attempt to maintain the PLP-myriocin imine 
bond. This unorthodox approach led to the observation of a 631.30153 Da species 
which corresponds very well to the predicated PLP:myriocin external aldimine 
(Figure 4-17) mass of  631.29902 Da (Figure 4-19).  
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Figure 4-19 Detection of the PLP-myriocin aldimine by LC-MS  
Left - Extracted ion chromatogram at m/z 631. Control enzyme shown in gray. Myriocin treated 
enzyme shown in black. The small peak at 5 minutes in the control reaction is of unknown origin and 
could relate to any small contaminant of mass 631 Da. Right - High-resolution mass spectrum of the 
PLP-myriocin aldimine, obtained by summing the spectra between t = 8−12 min. ([M + H]+ 
C29H48N2O11P; predicted m/z 631.29902; observed error 4.0 ppm). * denotes a contaminant. 
 
Measuring the mass of this key aldimine, combined with the UV-vis data, is the first 
conclusive evidence that myriocin acts on SPT in the hypothesized manner, 
confirming for the first time that myriocin forms an aldimine with PLP. The changes 
in the UV-vis spectrum provide strong evidence that myriocin binds in or near the 
active site displacing the initial internal PLP aldimine. 
Following confirmation of the correct inhibitory species fundamental inhibition 
studies were attempted. For the first time the effect of myriocin was analysed on 
purified SPT, with previous attempts to quantify myriocin inhibition having involved 
eukaryotic SPT expressed in whole cells and microsomal extracts.73, 145 The only 
exception to this was Ikushiro,162 who although unable to generate inhibition data for 
myriocin with purified bacterial SPT, managed to produce an apparent Kd for 
myriocin binding of 1.3 M suggesting myriocin had a 1000 fold higher affinity for 
SPT that L-serine. The use of whole cell assays makes the calculation of robust 
kinetic parameters impossible due to uncertainties over cellular permeability and 
substrate concentrations. Thus, in order to characterise myriocin potency, inhibition 
studies to date have relied on IC50 determination. The most fundamental inhibition 
parameter, Ki, proved the most difficult to obtain due to the very high affinity of 
myriocin for SPT. A typical inhibition assay contained 200 nM SPT while myriocin 
concentrations were varied between 80 nm and 80 μM. In assays approaching the 
lower end of the myriocin concentration range the concentration of myriocin is less 
than the enzyme concentration. The high affinity of myriocin impacts directly on the 
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steady state approximation that is fundamental to Michaelis Menten kinetics. 
Therefore the observed change in rates must be analysed using an equation that 
incorporates the variation in inhibitor concentration. The Morrison equation 
(Equation 4-1) was developed especially for “tight binding” inhibitors that break the 
steady state approximation.163  
 
Equation 4-1 The Morrison Equation 
 = measured velocity, o = velocity in the absence of inhibitor, Ki,app = the apparent equilibrium 
inhibition constant, I = inhibitor concentration, E = enzyme concentration. 
 
Running triplicate enzyme assays with saturating palmitoyl-CoA and L-serine 
concentrations, ten and twenty fold above their respective Km values and increasing 
myriocin concentrations produced a Ki for myriocin of 967 ± 98 nM (Figure 4-20). 
 
Figure 4-20 Inhibition of SPT by myriocin  
Initial rates from the DTNB assay plotted against increasing myriocin concentration (0.075, 0.150, 
0.312, 0.625, 1.25, 2.5, 5, 10, 20, 40, 80 M). Each assay contained 200 nM enzyme, 250 M 
palmitoyl-CoA, 20 mM L-serine, 0.2 mM DTNB and the appropriate myriocin standard. Data fitted 
using the Morrison equation. The Ki obtained for the PLP-myriocin aldimine is 967 ± 98 nM. 
 
The mode of inhibition of SPT by myriocin has been disputed in the literature, with 
Miyake et al. initially declaring the inhibition non-competitive in 1995.145 Almost ten 
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years later Ikushiro et al. suggested myriocin inhibition to be competitive.162 To 
settle the disagreement about the mode of inhibition, competition studies were 
carried out between myriocin and both substrates, L-serine and palmitoyl CoA. 
Following the non-Michaelis Menten type kinetics observed during the calculation of 
the Ki the nature of inhibition by SPT was determined using the Cha method.164 IC50 
values for the inhibitor were determined at fixed enzyme concentrations while 
systematically varying each substrate concentration. The linear increase in IC50 
values with varying L-serine and palmitoyl-CoA concentration, establishes myriocin 
as a competitive inhibitor for both L -serine and palmitoyl-CoA substrates (Figure 4-
21).  
 
Figure 4-21 Determination of the mode of action between AmSPT by the inhibitor myriocin 
A graphical method was employed to determine the mode of interaction between myriocin and SPT 
(in relation to the natural substrates L-serine and palmitoyl-CoA). Briefly, IC50 values were 
determined for myriocin at a fixed enzyme concentration (200 nM), whilst varying the concentration 
of a single substrate. Graphs were plotted of IC50 at varying concentrations of either L-serine, (Right) 
or palmitoyl-CoA, (Left). 
 
The differences in the concentration of L-serine required to inhibit 50% of the 
enzyme in comparison to palmitoyl-CoA can be seen on both the axis scales and the 
gradient of the line is a reflection upon the different binding efficiencies of the two 
substrates. The competitiveness for both substrates can be rationalised when viewed 
from a structural perspective. The PLP-myriocin aldimine shares structural features 
with both substrates, the long alkyl chain of myriocin mimics the alkyl chain of 
palmitoyl-CoA. While the carboxylic acid group and the hydroxymethyl at the head 
of the molecule mimic L-serine. Interestingly, the arrangement around carbon-2 of 
myriocin renders it in the D conformation but yet it still competes for L-serine. The 
lack of chiral specificity at the active site is not surprising after Ikushiro et al. 
showed that D-serine also interacts with bacterial SPT.162 Presumably this would 
proceed via the formation of a hypothesised D-serine-PLP external aldimine but the 
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existence of such species is solely inferred from UV-vis changes upon D-serine 
addition. The apparent Kd for D-serine is 10 mM, an order of magnitude larger than 
L-serine (1.4 mM), showing SPT displays a clear preference for the L enantiomer. D-
serine has also been shown to inhibit mammalian SPT with an IC50 of 0.3 mM in 
CHO cells with the inhibition thought to be caused by the inverse stereochemistry 
not allowing deprotonation at C-α.41, 165  
 
A great step forward in the understanding of myriocin inhibition came rather 
unexpectedly through time dependent rate analysis coupled with extended UV-vis 
analysis. Assaying SPT activity over 16 hours in the presence of myriocin showed 
that SPT remained inhibited by myriocin for at least this length of time. Interestingly 
UV-vis analysis performed at 25 oC over the same time period showed a more 
complex and surprising picture. Combining SPT and myriocin immediately produces 
the predicted dominant 430 nm peak, but monitoring this reaction every 30 minutes 
by collecting a fresh UV-vis spectrum shows the 430 nm peak is only stable for 1.5 
hours before it slowly diminishes. This reduction at 430 nm is followed by the 
concomitant increase in two new peaks at 331 and 400 nm, Figure 4-22. 
 
 
Figure 4-22 UV−vis analysis of the degradation of the myriocin-PLP aldimine in AmSPT 
The PLP-myriocin external aldimine (solid line) is stable for 90 min, before a decrease at 430 nm is 
observed, which is accompanied by a concomitant increase at 331 and 400 nm over 16 h (dotted and 
dashed lines). 
 
The change in the UV-vis spectrum suggests the PLP:myriocin aldimine is unstable 
and degrades to a previously unseen PLP derivative. Surprisingly, rate analysis over 
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greater than 1.5 hours indicating that the new myriocin degradation product must 
also be inhibitory. During initial attempts to understand the changing UV-vis 
spectrum the incubation temperature was lowered to 4 oC. This resulted in the 
PLP:myriocin aldimine remaining stable for greater than 16 hours. (Figure 4-23) 
 
Figure 4-23 Effect of variation in temperature upon PLP-myriocin aldimine stability 
AmSPT (40 M) was treated with 200 M myriocin, and incubated for 16 hours at either 25 °C (Left) 
or 4 °C (Right). UV-vis spectra after addition of myriocin at time 10 minutes (black trace) and 16 
hours (red trace). 
 
The temperature dependence of the degradation reaction facilitated the study of the 
PLP:myriocin aldimine as this allowed the lifetime of the species to be easily 
controlled. It was reasoned that degradation of the PLP:myriocin external aldimine 
could be hampering crystal formation and that the increase stability at 4 oC could be 
utilised to aid crystal trials. Therefore crystal plates were set up, incubated and 
monitored at 4 oC for four weeks but these attempts also failed to produce any 
appropriately sized crystals.  
 
The absorbance maxima at 400 and 333 nm that arise following the disappearance of 
the myriocin-PLP aldimine, had not previously been observed in either spSPT or 
AmSPT, with the closest UV-vis spectrum arising from the K265A AmSPT mutant. 
The K265A AmSPT has no active site lysine and is therefore unable to bind PLP in 
the internal aldimine form but nevertheless, still purifies with PLP bound to the 
enzyme, presumably in a non-covalent manner. The resulting UV-vis spectrum 
shares very similar absorbance maxima to the myriocin degradation product (Figure 
4-24, solid line). Following the addition of five equivalents of myriocin, K265A 
AmSPT responds in in a similar manner to wild-type AmSPT (Figure 4-24, dotted 
line). Both initial PLP internal aldimine peaks are replaced by one large absorbance 
at 425 nm, which is now known to correspond to the PLP:myriocin external 
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aldimine does not degrade (Figure 4-24, dashed and dotted lines). The longevity of 
the 425 nm peak (PLP:myriocin external aldimine) under the same conditions but 
with single amino acid substitution demonstrates the essential involvement of the 
active-site lysine 265 in the degradation pathway.  
 
 
Figure 4-24 UV−vis analysis of K265A AmSPT 
After de-salting K265A AmSPT (40 M) showed two absorbance maxima at 326 and 402 nm (solid 
line). Upon addition of 200 M myriocin, an immediate shift to a single peak at 425 nm occurred 
(dotted line), indicating the formation of a PLP-myriocin aldimine complex. Over 16 hours this 
spectrum remains unchanged (dashed line), indicating that the PLP-myriocin aldimine complex is not 
degraded by this mutant enzyme.  
 
Combining the formation of a new species, as observed in the UV-vis spectrum, after 
prolonged incubation of myriocin and SPT with the continued SPT inhibition it was 
hypothesised that the PLP:myriocin aldimine degraded over time to produce a second 
inhibitory species. As the degradation product(s) also inhibit SPT the nature of the 
inhibition of SPT by myriocin was probed both before and after 16 hours of 
incubation. To test the reversibility of the inhibition, the PLP:myriocin aldimine and 
degradation product were first generated by incubation of SPT with the inhibitor for 
10 minutes and 16 hours respectively at 25 °C. After this incubation period the 
temperature was lowered to 4 °C to stop further conversion and extensive dialysis 
against buffer containing 25 μM fresh PLP was performed for 24 hours. Aliquots 
were removed from the dialysate at specific time points (0, 3 and 24 hours) and 
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Figure 4-25 Relative enzymatic activity after removal of inhibiting species by dialysis 
40 M SPT was inhibited with 200 M myriocin and incubated for 10 minutes (white bars) or 16 
hours (grey bars) at 25 °C before removal of myriocin by extensive dialysis. The enzymatic activity 
was then determined at 0 hours, 3 hours, and 24 hours after dialysis. 
For the enzyme incubated with myriocin for the shorter time (10 mins), then dialysed 
for 3 hours, no significant activity was recovered; however, dialysis for 24 hours 
recovered 60% enzymatic activity (Figure 4-25, white bars). This regain in 
enzymatic activity was also accompanied by a change in the UV-vis spectrum back 
to the internal aldimine form (λmax 333 and 420 nm). Taken together, this data from 
short, 10 minute incubations of SPT with myriocin is consistent with the formation 
of an initial enzyme-inhibitor complex which is non-covalent in nature and 
reversible, albeit with a very slow off rate (koff). This provides evidence to support 
our assignment of the PLP:myriocin aldimine as the initial inhibitory species. In 
contrast, for the enzyme pre-incubated with myriocin for 16 hours, no detectable 
regain in activity was observed after dialysis either at 3 or 24 hours (Figure 4-25, 
grey bars); indicating that this second, newly-formed species acts as an irreversible 
inhibitor of SPT. 
Analysis of the vast PLP literature reveals PLP is capable of catalysing many varying 
reactions with the end product being dictated not only by the substrate but also the 
protein scaffold that composes the active-site. Although most PLP enzymes have a 
conserved PLP binding pocket there is significant variation in proximal amino acids. 
This variation allows different hydrogen bonds and electrostatic interactions to exist 
in different enzymes producing differing propensities to form one product over 
another. An investigation of PLP catalysed reactions revealed serine 
hydroxymethyltransferase (SHMT) and cholerae autoinducer-1 synthase (CqsA) to 
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have mechanisms that could be applied to the breakdown of the PLP:myriocin 
external aldimine (Figure 4-26).12, 166-167 CqsA is a PLP dependent synthase 
responsible for the condensation of either L-threonine, L-2-aminobutyric acid or S-
adenosylmethionine and decanoyl-coenzyme A to synthesise a precursor of the 
cholera autoinducer-1, an important molecule in quorum sensing. The hydroxyl 
group on the  to both of the above examples 




Figure 4-26 CqsA and Serine hydroxymethyltransferase mechanisms 
(a) - CqsA mechanism shown for simplicity with L-threonine as the substrate. Deprotonation, 
formation of a carbonyl and then cleavage of the C-C bond. (a) - Serine hydroxymethyltransferase 
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The cleavage of the C-C bond via hydroxyl deprotonation and carbonyl formation 
is named a “retro-aldol” like reaction. The possibility that the PLP:myriocin aldimine 
undergoes a retro-aldol reaction would produce a long chain aldehyde and a PLP:D-
serine aldimine. The proposed mechanism a retro-aldol degradation of the 
PLP:myriocin aldimine is shown in Figure 4-27.  
  
Figure 4-27 The proposed “retro-aldol like” mechanism for the observed degradation of the 
PLP-myriocin aldimine 
Myriocin, undergoes fast transamination with the internal aldimine, releasing Lys265 and forming the 
PLP-myriocin aldimine inhibitory complex. This inhibitory complex is slowly degraded by 
deprotonation of the myriocin C3-hydroxyl with C2-C3 bond cleavage and movement of electrons into 
the pyridine ring of PLP. This results in the formation of a 2-hydroxyl-C18 aldehyde species and a 
PLP-D-serine aldimine. 
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To test this hypothetical breakdown mechanism, evidence of one of the products was 
sought. As any PLP:D-serine aldimine would immediately dissociate in solution due 
to the relatively high D-serine Kd (10 mM) quantification of the long chain aldehyde 
was attempted. Unequivocal identification was attempted via mass spectrometry with 
the potential aldehyde functionality being utilised through the use of hydrazides. 
Initially derivatisation of the aldehyde with 2,4-dinitrophenylhydrazine (Figure 4-28) 
was attempted but repeated reactions, extractions and analysis showed no masses 
corresponding to a hydrazone being formed from the putative 18-carbon aldehyde.  
 
 
Figure 4-28 Aldehyde derivatisation agents. 
 
Following the work of Berdyshev et al. with the S1PL and his quantification of the 
product hexadecenal using semicarbazide (Figure 4-28) and mass spectrometry a 
similar approach was attempted.168-169 Multiple permutations of the published 
method all failed to yield any results. After discussion with Professor Al Merrill 
(Georgia Tech, USA), an expert in sphingolipid mass spectrometry, Girard’s reagent 
T was used as a derivatisation agent prior to mass spectrometry analysis.170 Girard 
developed two quaternary ammonium salts for derivatisation of aldehydes prior to 
crystallisation in order to aid separation (Figure 4-28). More recently the same 
reagents have been used to add a charged moiety to aldehydes to aid ionisation.171 
Again this method failed to produce any ions attributable to the derivative of the 
putative 18-carbon aldehyde. Failure to detect any aldehyde suggested it either didn’t 
exist or was not free in solution ready to facilitate derivatisation. Focussing on the 
later hypothesis intact protein mass spectrometry was undertaken based on the 
knowledge that long chain aldehydes are relatively reactive and could potentially 
covalently modify any nucleophilic residues. Comparison of the mass spectrum 
before and 16 hours after myriocin addition showed a clear proportion of protein 
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corresponds exactly to the condensation product of the C18 aldehyde product that 
would be formed from a retro-aldol type degradation of myriocin. 
 
 
Figure 4-29 Mass spectrometry analysis of the myriocin-derived covalent modification of SPT 
Left - Intact protein mass spectrometry of AmSPT (40 M) before (top) and after (bottom) 16 hour 
treatment with 200 M myriocin at 25 °C. SPT displays an average neutral mass of 47231 Da. After 
myriocin treatment a prominent new species of average mass 47509 is observed (mass +278 Da). 
Minor peaks highlighted by * arise from -N-gluconoylation of the His-tag. Right - The myriocin-
derived modification.  
In an attempt to increase the proportion of the modified protein in the sample, 
attempts were made to reduce the highly likely imine bond attachment of the 
myriocin fragment to SPT. Sodium borohydride was used to convert the labile imine 
to the more stable secondary amine. Mass analysis observed the modified mass had 
increased to Δ282.24 Da after the reduction with sodium borohydride. The difference 
of 4 Da is most likely due to both the reduction of the octadecenal-protein imine 












C18-aldehyde derived from myriocin
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Figure 4-30 Chemical reduction of the covalent adduct formed by myriocin degradation 
(a) - Top, deconvoluted intact protein mass spectrum after incubation with myriocin for 18 hours at 
25 °C. The MS displays two species - 47,231 Da, consistent with apo-SPT; and the unknown 
myriocin-derived covalent adduct at 47,509 Da (mass +278 Da). Bottom, deconvoluted intact 
protein mass spectrum after chemical reduction with 10 mM NaBH4. The MS displays two new 
species – 47,462 Da (mass +231 Da), which is consistent with the reduced SPT-PLP internal 
aldimine; and 47,513 Da (mass +282 Da). Peaks highlighted by * arise from -N-Gluconoylation of 
the His-tag. (b) - Proposed chemistry occurring upon reduction of the myriocin-induced SPT covalent 
adduct. Octadecenal, condensation with Lys265 produces the imine species (mass 278 Da; 
+C18H30O2). Chemical reduction then produces the observed hydroxy-amine adduct (mass +282 Da; 
+C18H34O2).  (c) - Sequence coverage achieved when analysing myriocin-modified SPT enzyme. 
Amino acids highlighted in bold were observed in the peptide mass fingerprint (Appendix 2). The 
myriocin derived modification was isolated to a single site between Glu245 and Lys280 (underlined); 
this sequence contains a single internal lysine residue, Lys265 (highlighted by the arrow). 
 
After reduction, the protein mass spectrum displayed two peaks. One corresponding 
to the doubly reduced modification (Figure 4-30A blue peak) and an unknown Δmass 
+231 Da species. Literature consultation later showed the Δ231 Da species to arise 
from reduction of PLP:lysine internal aldimine to the enzyme. The location of the 
modification was determined by trypsin digestion followed by peptide analysis. After 
formation of the aldehyde sodium borohydride was again added to reduce the imine 
linkage before trypsin was used to digest SPT into fragments for mass spectrometry 
analysis. Analysis achieved overall sequence coverage of 89%, with three peptides 
assigned as containing the Δmass 282.24 Da modification (+C18H34O2) (Figure 4-
30C). All three modified peptides covered the region around lysine265. Comparison 
of the modified peptides determined the active site lysine265 as site of modification. 
The detection of a covalently linked octadecenal on lysine265 of SPT supports the 
suggested retro-aldol mechanism. The changes in the UV-vis spectrum (Figure 4-22) 
1 
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are now known to show the disappearance of the PLP:myriocin aldimine and the 
formation of PLP:D-serine aldimine. The shifted 333 and 400 nm max would not 
usually be expected to arise from a PLP:D-serine aldimine but the difference can be 
attributed to the presence of the lysine modification. The covalent modification of the 
active site lysine also explains the prolonged and irreversible inhibition observed 
after the myriocin incubation (Figure 4-25).  
The turnover of myriocin in the active site was believed to be a contributing factor in 
previously unsuccessful myriocin-SPT co-crystal trials. The knowledge that myriocin 
is broken down via a retro-aldol mechanism can be utilised to probe the effect of 
myriocin turnover on crystallisation. All retro-aldol reactions initially require a base 
to deprotonate the hydroxyl group. Analysis of the SPT active site from previous 
crystal structures places lysine265 in the ideal position, therefore co-crystallisation of 
myriocin and the K265A SPT mutant was attempted. The stability of the 
PLP:myriocin aldimine for longer than 16 hours when formed with the K265A 
AmSPT also confirms the involvement of the active site lysine. Based on this 
increased stability of the myriocin complex crystal trials were attempted with K265A 
AmSPT and myriocin. Working with Professor Jim Naismith and Dr Stephen 
McMahon extensive crystal trials with both commercial and in-house precipitant 
screens were undertaken. Following an initial hit, screen optimisation determined the 
optimal conditions to be 32% PEG MME 2000, 0.1 M HEPES pH 7.5 and a 
protein:precipitant ratio of 1:1. Using these conditions crystals were grown by 
vapour drop diffusion at 20 °C over the course of 2 weeks and are readily 
reproducible. Several data sets were collected but only the highest resolution (1.6 Å) 
structure was completely refined. The structure was solved by molecular replacement 
using an already published SPT-PLP internal aldimine structure (PDB code 2JG2)100 
and contained a canonical dimer in the asymmetric unit (Table 4-3 and Figure 4-31).  
  
 














































      Table 4-3 Crystallographic statistics for SPT K265A PLP-decarboxymyriocin 
  
Data Collection    
Space Group P 21 21 21 
Cell dimensions  
a, b, c (Å) 61.9, 98.7, 133.2 
α, β, γ (°) 90, 90, 90 
Resolution (Å)* 
(high resolution) 
56.14 – 1.62 
(1.66 - 1.62) 
Rmerge 0.067 (0.497) 
I/σ(I) 10.8 (2.3) 
Completeness (%) 98.9 (99.7) 
Average Redundancy 3.6 (3.8) 
Vm (Å3/Da) 2.25 
Solvent (%) 45.2 
Refinement  
Unique reflections 103044 
Rwork / Rfree 19.0 / 21.2  
Geometric deviations  
Bonds (Å) / Angles (°) 0.009 / 1.43 




PLP-Myriocin Aldimine 56 
B factors (Å2)  
Protein 19.3 
Water 27.9 
PLP-Myriocin Aldimine 33.3 
Glycerol 32.8 
Ramachandran  
Allowed / disallowed (%) 97.3 / 0 
Molprobity score / centile 1.25 / 97 
PDB code 4BMK 
*Values in parentheses refer to the highest resolution shell 
 
   94
 
Figure 4-31 The structure of SPT K265A PLP-decarboxymyriocin aldimine inhibitory complex 
A - The biological SPT dimer of the decarboxylated myriocin complex. The protein is shown as a 
cartoon with one subunit coloured blue and the other white. The PLP external aldimine of the 
decarboxylated myriocin is shown in space fill with carbons coloured yellow, nitrogen blue, oygen red 
and phosphorous orange. B - Left, The Fo-Fc map (blue chicken wire contoured at 1.8σ, carve radius 
1.5Å) calculated from a model which had never contained either PLP or myriocin. Atoms are coloured 
as in A. Right, the final Fo-Fc map contoured at 0.85σ with a carve radius 1.8Å. C - Detailed 
representation of the active site interactions, carbon atoms are coloured yellow and shown in sticks for 
the PLP-decarboxymyriocin aldimine. Carbon atoms in protein side chains are shown as white sticks, 
others atoms are coloured as in A. The hydrocarbon chain of the myriocin inserts into a hydrophobic 
pocket.  
 
The mobility/flexibility of the acyl chain prevented the assignment of a structure 
beyond carbon 9 of myriocin. Nevertheless difference electron density revealed a 
PLP:myriocin aldimine complex had formed (Figure 4-31B). The myriocin 
stereochemistry is retained - the Z configuration of the double bond at position C6 
and cis diol geometry at positions C3 and C4. It was surprising to discover that the 
density indicates that myriocin had undergone loss of the carboxylate from the C2 
position to form a PLP:decarboxymyriocin aldimine. The model was built reasoning 
the replacement of the carboxylate with a proton (sp3 hybridised carbon) but the 
resolution on its own is not sufficient to distinguish an sp3 from an sp2 carbon (Figure 
4-31B). As had been noted previously, residues from both SPT subunits are involved 
in PLP binding and the active site is at the dimer interface.29 Comparison of this 
complex with the wild type SPT:PLP-L-serine external aldimine complex (PDB code 
2W8J)29 reveals essentially the same positioning of the PLP rings in both structures 
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Figure 4-32 Overlay of myriocin K265A AmSPT and PLP-L-ser spSPT 
Superposition of the PLP-decarboxymyriocin external aldimine (key sidechains and secondary 
structure rendered in grey and the aldimine coloured yellow) with the PLP-L-serine external aldimine 
2W8J (key sidechains and secondary structure rendered in blue and the aldimine carbons coloured 
pink) The key catalytic Lys265 residue is mutated to Ala in the decarboxylated myriocin complex. 
 
Moreover, many key active site residues (His159, Asp231, His234) adopt similar 
positions. However Arg378, which is involved in a key electrostatic interaction with 
the carboxylate of L-serine in the SPT:PLP-L-serine external aldimine structure, is 
swung out of the active site with concomitant change in the important mobile loop 
378-RPPATP-383; both the loop and Arg378 are partially disordered in the new 
complex. These changes are presumably the result of accommodating the extended 
hydrophobic tail of myriocin. Also Arg390, a conserved residue that is required for 
product formation in the SPT catalytic cycle, adjusts its side chain conformation and 
makes interactions with both Tyr73 and the C4 hydroxyl of myriocin.172 Modelling 
the SPT K265A PLP:myriocin external aldimine complex places the carboxylate 
perpendicular to the PLP (“Dunathan conformation”) that would allow 
decarboxylation by the mechanism proposed in Figure 4-33.  
 
Figure 4-33 Decarboxylation mechanism 
Proposed mechanism to account for the PLP-decarboxymyriocin external aldimine observed in the 
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However, its extreme slowness relative to bona fide PLP-dependent decarboxylases, 
cautions that the PLP-myriocin aldimine in K265A is not optimally aligned for this 
reaction. Evidence of the decarboxylation was initially only ever discovered 
following the two-week crystallisation process. In an attempt to produce the 
PLP:decaroxylatedmyriocin aldimine in solution the K265A mutant was incubated 
with myriocin and then stored at 25 oC. Periodic mass spectrometry analysis showed 
the PLP:decaroxylatedmyriocin aldimine only formed after 7 days incubation thus 
emphasising the extremely slow nature of the reaction most likely arising from the 
sub-optimal alignment (Figure 4-34).  
 
 
Figure 4-34 Mass spectrometry analysis of the reaction between SPT K265A and myriocin 
 (a) Detection of the PLP-myriocin aldimine (11) in the SPT K265A mutant by LC-MS. MS obtained 
by summing the spectra between t = 8-12 minutes. ([M+H]+ C29H48N2O11P; predicted m/z 631.29902; 
observed error 3.2ppm). * denotes a contaminant. 
(b) Detection of the PLP-decarboxymyriocin aldimine (15) in the SPT K265A mutant by LC-MS. 
This species was only observed after incubation of myriocin (200 µM) with SPT K265A (40 µM) for 
7 days at room temperature. MS obtained by summing the spectra between t = 10-12 minutes. 
([M+H]+ C28H48N2O9P; predicted m/z 587.30919; observed error 6.1ppm).  
 
It is worth noting that the precise orientation of the PLP:myriocin aldimine required 
for decarboxylation may not be achievable in the wild type enzyme. In the wild type 
SPT the side chain of K265 would be very close to or perhaps clash with the 
carboxylate, distorting it out of the Dunathan conformation or stabilising the 
carboxylate by an ionic interaction. In previous studies of the SPT:PLP-L-serine 
external aldimine complex of S. paucimobilis SPT it was revealed that the 
carboxylate group is held in a specific orientation by salt bridges with Arg378 and 
His159.29, 172 In this arrangement decarboxylation is not favoured, rather 
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deprotonation of the L-serine at C by K265 is achieved only upon a conformational 
change caused by palmitoyl-CoA binding.29, 115 The CH2OH head group of myriocin 
interacts with the 5-phosphate of PLP in the same manner as the hydroxyl group 
from L-serine (Figure 4-35).28 The 5’-phosphate of PLP interacts with both ligand 




Figure 4-35 Analysis of the PLP phosphate binding via visualisation of the “phosphate cup” 
Left. PLP-L-serine aldimine (PDB code 2W8J) showing residues from monomer A (green) and 
monomer B (blue) involved in binding the 5’-phosphate of PLP. Right. PLP-decarboxymyriocin 
aldimine showing residues from monomer A (green) and monomer B (blue) involved in binding the 
phosphate of PLP. Despite the opposite stereochemistry of myriocin at C compared with L-serine, 
the C1 hydroxyl still hydrogen bonds to the 5’-phosphate of PLP. 
 
Elsewhere the 3,4-cis diol of decarboxymyriocin makes hydrogen bonds to the 
protein, notably the 3-hydroxy of myriocin with the important catalytic residue 
His159; this interaction would be expected to be preserved in the wild type 
SPT:myriocin complex. Some insight into the binding of myriocin can be inferred 
from the literature but most of the published structure activity studies involving 
myriocin were concerned with myriocin’s immunosuppressant properties which were 
later shown not to arise from its ability to inhibit SPT. Therefore, it is unknown at 
which point in the selective removal of the functional groups from myriocin as part 
of the process of developing FTY720 that SPT inhibition was lost, as it has now been 
confirmed that FTY720 does not inhibit SPT.147, 173 However, the published work 
probing the SAR of  sphingofungin B suggests an electron rich oxygen is required at 
carbon-14 but not necessarily as part of a carbonyl moiety and that the 
stereochemistry at the ,  and  carbons are crucial to SPT inhibition.133, 174 The 
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decarboxymyriocin may be changed by the presence of Lys265 but at least some of 
the same network seems certain to persist. This network involves the same residues 
that interact with the carboxylate of the PLP:L-serine external aldimine. These 
interactions rationalise the competitive inhibition with L-serine. Accompanying these 
interactions are movements of the side-chains of Tyr73, Arg378 and Arg390 as well 
as a displacement of a key conserved stretch of amino acids (RPPATP). The carbon 
tail of myriocin binds in a similar orientation to the decanoyl-tail of the PLP-product 
external aldimine observed bound in the crystal structure of the related AOS enzyme 
CqsA from Vibrio cholera consistent with our hypothesis that myriocin mimics the 
condensation intermediate (Figure 4-36).166  
 
Figure 4-36 Overlay of myriocin K265A AmSPT and PLP-deconyl CqsA 
Active site geometry of the PLP-decarboxymyriocin external aldimine structure (key sidechains and 
secondary structure rendered in grey; PBD 4BMK) with the V. cholera CqsA enzyme with the trapped 
product external aldimine bound (key sidechains and secondary structure rendered in green; PBD 
2WKA). The PLP-decarboxymyriocin aldimine (yellow) overlays extremely well with the C10-
product external aldimine in the CqsA active site (lilac). It is clear that both species occupy the same 
hydrophobic pocket. 
 
As well as SHMT and CqsA the proposed mechanism for myriocin degradation is 
also reminiscent of the mechanism of the PLP-dependent S1PL. S1PL is the terminal 
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S1P.51 During the catalytic cycle of S1PL, the C3 hydroxyl group of the key 
PLP:S1P external aldimine is deprotonated, which leads to C2-C3 bond cleavage and 
production of hexadecenal and phosphoethanolamine. The similarity of the long 
chain aldehyde product of S1PL to the suicide-inhibitor produced by SPT-catalysed 
breakdown of myriocin is striking. This suggested a possible feedback mechanism 
whereby the end product of the sphingolipid pathway, hexadecenal, may regulate 
sphingolipid biosynthesis by inhibiting SPT, the enzyme that catalyses the first step 
in de novo sphingolipid synthesis. Indeed, in exciting preliminary in vitro studies, it 
was found that hexadecanal inhibits SPT with an IC50 of 144 μM (Figure 4-37). 
 
Figure 4-37 Dose response curve showing changes in relative rate versus the log of hexadecanal 
concentration. 
Activity was quantified by monitoring the reaction of the co-product CoASH with DTNB. The 
reaction was performed on a 250 μL scale, SPT (200 nM) was incubated with L-serine (20 mM) in the 
presence of varying hexadecanal concentrations (20, 40, 80, 125, 250, 500 and 1000 μM). The 
reaction was started by the addition of the second substrate palmitoyl-CoA (250 μM).  
 
Following the success of the myriocin crystal trials and the availability of the newly 
optimised conditions, crystal trials were attempted with compounds provided in a 
collaborative PhD agreement by Dr Howard Broughton at Lilly Pharmaceuticals. 
Lilly were interested in inhibition of human SPT but acknowledged that the bacterial 
SPT would provide a good model and provided 40 of their lead SPT inhibitors 
(Appendix 3). Lilly had access to both a bacterial and human SPT assay with some 
of these compounds showing low nanomolar inhibition. Based upon their IC50 values 
and the priority level given to the compounds by Lilly, four inhibitors were taken 
forward into crystal trials (Figure 4-38). 
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Figure 4-38 Selected Lilly inhibitors taken forward for crystal trials 
 
As inhibition data was already available and a co-crystal structure would yield the 
most relevant information for a drug development programme the four compounds 
were solely committed to crystal trials. Unlike myriocin, no degradation of the 
inhibitor was expected and to gain maximum structural information co-crystallisation 
was attempted with WT AmSPT. Initial screens centred around the optimal 
conditions determined for myriocin but this yielded no results. Starting the screening 
process afresh for each of the four compounds also provided no viable crystals. Due 
to time constraints, the success of the myriocin study and limited access to the 
crystallography lab in St. Andrews no further work was undertaken with these 
compounds. 
The initial aim of the work with myriocin was to delineate the structural and 
mechanistic details of how myriocin inhibits SPT, and in doing so it has revealed 
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Figure 4-39 Summary of myriocin’s dual mode of action. (Inhibitory species highlighted in 
boxes) 
 Left: myriocin reacts with PLP in the active site to form the inhibitory PLP:myriocin aldimine, this 
species is stable for greater than 1 h at physiological temperature with inhibition being reversible upon 
addition of excess PLP. Right: PLP-myriocin aldimine decomposes over 16 h, at physiological 
temperature, to produce a long chain aldehyde that reacts with the active site lysine to form an imine, 
thus rendering the enzyme inactive. This covalent modification can be classed as suicide inhibition. 
 
These results demonstrate that, as predicted, myriocin acts as a classical intermediate 
mimic inhibitor with nanomolar affinity for its target. However, once bound in the 
active site the inhibitory species is broken down by the enzyme to generate a reactive 
product which acts as a suicide inhibitor by covalent modification of a key active site 
residue conserved in all SPTs. 
The PLP-catalyzed retro-aldol reaction that breaks down the myriocin calls to mind 
other important PLP-dependent enzymes that use the cofactor to catalyze carbon-
carbon bond cleavage. SHMT, which is involved in one carbon metabolism, and 
CqsA, which produces quorum sensing molecules, both use a proposed retro-aldol 
mechanism to generate glycine from L-serine and L-threonine, respectively. 
Furthermore, the proposed mechanism for myriocin degradation is reminiscent of the 
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mechanism of the PLP-dependent S1PL, the terminal enzyme of sphingolipid 
biosynthesis that catalyzes the breakdown of S1P. 
The high sequence homology between the SPTs from bacteria and other higher order 
species suggests that the mechanism of myriocin inhibition is conserved and indeed 
studies on the human enzyme are already under way within the Campopiano group. 
The unprecedented combination of tight binding and mechanism-based inactivation 
within a single molecule described herein, has the potential to inform the design of a 
new class of inhibitors for SPT and other PLP-dependent enzymes. 
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4.3 SPT Fusions 
The main difference between SPTs from eukaryotic species (such as humans, plants 
and yeast) and bacteria was, until recently, believed to be the existence of two 
distinct but structurally similar subunits that come together to form a heterodimer in 
humans. Moreover, small subunits such as Tsc3p, ssSPT and ORMs act as either 
positive or negative regulators of SPT activity in these organisms and can provide a 
mechanism to control sphingolipid biosynthesis/metabolic flux when demand is 
either high or low. In contrast, bacterial SPT consist of only one subunit that forms a 
homodimeric complex with no small regulatory subunits involved. An interesting 
discovery made by our group was that the SPT from S. wittichii is coded in the same 
open reading frame as an unusual acyl-carrier protein (ACP) possibly suggesting its 
substrate is an acyl-ACP rather than an acyl-CoA.175 ACPs play key roles in fatty 
acid biosynthesis so this may allow regulation of sphingolipid biosynthesis by 
linking it to fatty acid metabolism. Since bacterial SPTs are relatively simple 
compared with their eukaryotic counterparts the utility of bacterial SPT as a 
structural model for the human protein was relatively limited, but still extensively 
utilised due to the intractability of human SPT to current biochemical methods. 
Following the discovery of a natural viral SPT fusion in the Coccolithovirus in 
2005,108 the concept of synthetic SPT fusions quickly developed and led to the 
publication of both synthetic yeast and human fusions by Dunn and colleagues in 
2006.109 Interestingly, another natural AOS fusion has been discovered in fumonisin 
biosynthesis, where Fum8p consists of two distinct domains that each show high 
sequence homologoy to lcb1 or lcb2.176 This natural fusion condenses L-alanine to 
stearoyl-ACP to form a key intermediate in fumonisin biosynthesis and further 
proves the validity of fusion proteins.  
Unfortunately the fusing of the two yeast proteins by Dunn et al. caused a 70% drop 
in activity with the added deleterious effect of causing a change in substrate 
specificity from C-16 to C-14.109 This change in substrate specificity suggests the 
folding of the two regions has somehow impeded the active-site and highlights the 
problems of creating synthetic fusions. Ferreira and colleagues have studied the 
structure and mechanism of the AOS family member ALAS involved in heme 
biosynthesis.177 They found that an ALAS fusion (2xALAS) was more active than 
the wild-type ALAS enzyme possibly by reducing the impact of rate limiting steps in 
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the mechanism.178 They have also generated ALAS/AONS fusions to study the 
possibility that subunits from different AOS families can interact with each other 
with limited success. The fusion work of Dunn and Ferreira highlights the 
advantages to fusion proteins, mainly the ability to circumvent the difficulty in over 
expressing and purifying stoichiometric quantities of each subunit. The advantage of 
any bacterial fusion would hopefully be in increased solubility leading to the ability 
to purify the enzyme therefore allowing robust kinetic analysis. In an attempt to 
make a more realistic model of the human protein complex from the bacterial 
enzyme our aim was to prepare a fusion that had one LCB1-like subunit lacking 
PLP-binding residues and the other mimicking LCB2. If it folded as a “monomer” it 
would be predicted to only have one PLP-binding active site. The PLP binding 
residues that had been naturally evolved out of the human lcb1 subunit were mapped 
to spSPT and mutated (Figure 4-40, Top). The four key PLP binding residues 
His159, Asp231, His234 and Lys265 were mutated to the corresponding amino acids 
from lcb1 before the quadruple mutant is fused to a second active spSPT (Figure 4-
40, Bottom C). As a control a fusion that had two wild-type SPTs linked together 
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Figure 4-40 Top - Amino acid sequence alignment of human lcb1 and spSPT. Bottom - Cartoon 
representation of the fusion project 
Top - Mutated residues are higlihghted in blue. Key - * (asterisk) indicates positions which have fully 
conserved residues, : (colon) indicates conservation between groups of strongly similar properties and 
. (full stop) indicates conservation between groups of weakly similar properties.  
Bottom (a) - Two subunits of human SPT showing membrane spanning domains, the PLP binding 
site and the heterodimeric nature of the complex (b) - Bacterial spSPT showing the only subunit and 
homodimeric nature of the soluble complex. (c) - The natural Coccolithovirus fusion arranged with 
the PLP binding protein first. (d) - The proposed arrangement of the bacterial fusion. 
 
The two bacterial subunits will be arranged in a similar manner as the viral fusion 
with the PLP binding; lcb2 like, subunit being at the N-terminus followed by the 
inactive, lcb1 like, subunit (Figure 4-40). 
 
lbc1 53 kDa  473 AA lcb2 63 kDa  562 AA 
 spSPT  45kDa 420 AA 
Fused viral SPT2‐SPT1  100 kDa 870 AA 
Key:      Membrane spanning domain            PLP binding site              TEV Protease Site    





Human lcb1          MATATEQWVLVEMVQALYEAPAYHLILEGILILWIIRLLFSKTYKLQERSDLTVKEKEEL 60  
spSPT               ---------MTEAAAQPHALPADAPDIA-------------PERDLLSKFDGLIAERQKL 38 
                             :.* .   :  **    :                 .* .: *  : *:::*   
Human lcb1          IEEWQPEPLVPPVPKDHPALNYNIVSGPPSHKTVVNGKECINFASFNFLGLLDNPRVKAA 120  
spSPT               LDSGVTDPFAIVMEQVKSPT-----------EAVIRGKDTILLGTYNYMGMTFDPDVIAA 87 
                    ::.  .:*:.  : : :..            ::*:.**: * :.::*::*:  :* * **   
Human lcb1          ALASLKKYGVGTCGPRGFYGTFDVHLDLEDRLAKFMKTEEAIIYSYGFATIASAIPAYSK 180  
spSPT               GKEALEKFGSGTNGSRMLNGTFHDHMEVEQALRDFYGTTGAIVFSTGYMANLGIISTLAG 147 
                    .  :*:*:* ** *.* : ***. *:::*: * .*  *  **::* *: :  . *.: :    
Human lcb1          RGDIVFVDRAACFAIQKGLQASRSDIKLFKHNDMADLERLLKEQEIEDQKNPRKARVTRR 240  
spSPT               KGEYVILDADSHASIYDGCQQGNAEIVRFRHNSVEDLDKRLG----------RLPKEPAK 197 
                    :*: *::*  :  :* .* * ..::*  *:**.: **:: *           * .: . :   
Human lcb1          FIVVEGLYMNTGTICPLPELVKLKYKYKARIFLEESLSFGVLGEHGRGVTEHYGINIDDI 300  
spSPT               LVVLEGVYSMLGDIAPLKEMVAVAKKHGAMVLVDEAHSMGFFGPNGRGVYEAQGLEG-QI 256 
                    ::*:**:*   * *.** *:* :  *: * ::::*: *:*.:* :**** *  *::  :*   
Human lcb1          DLISANMENALASIGGFCCGRSFVIDHQRLSGQGYCFSASLPPLLAAAAIEALNIMEENP 360  
spSPT               DFVVGTFSKSVGTVGGFVVSNHPKFEAVRLACRPYIFTASLPPSVVATATTSIRKLMTAH 316 
                    *:: ..:.:::.::***  ..   ::  **: : * *:***** :.*:*  ::. :       
Human lcb1          GIFAVLKEKCGQIHKALQGISGLKVVGESLSPAFHLQLEESTGSREQDVRLLQEIVDQCM 420  
spSPT               EKRERLWSNARALHGGLKAMG-FRLGTETCDSAIVAVMLE---DQEQAAMMWQALLDGGL 372 
                         * .:.  :* .*:.:. :::  *: ..*:   : *   .:** . : * ::*  :   
Human lcb1          NRSIALTQARYLEKEEKCLPPPSIRVVVTVEQTEEELERAASTIKEVAQAVLL-- 473  
spSPT               YVNMARPPATPAG-------TFLLRCSICAEHTPAQIQTVLGMFQAAGRAVGVIG 420 
                      .:* . *           .  :*  : .*:*  ::: . . :: ..:** :   
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The production of a plasmid with two identical 1200 base pair sequences had 
previously caused problems, mostly likely from recombination of the plasmid 
construct and loop formation. The ability to combine two DNA sequences encoding 
for the same protein into one plasmid was only made possible by using two 
sequences that utilised different codons for the same amino acids. AmSPT had been 
gifted to the lab from Professor Teresa Dunn and was originally synthesised as a 
synthetic gene codon optimised for Arabidopsis expression. The fusion project had 
been previously started within the laboratory by Dr Marine Raman and resulted in a 
wild type fusion, two fused wild type SPT subunits, already being available. The two 
subunits of SPT were linked by Tobacco Etch Virus (TEV) protease site with the 
intention of cleaving the fusion after purification to check the fidelity of the 
individual monomers. Monomeric spSPT had previously been produced with three of 
the four desired PLP binding mutations, D231E, H234L and K265N. Site direct 
mutagenesis (for primers see Table 3-4) was used to make the final targeted fourth 
mutation, H159C. A double Age1 and Xho1 digest was then used to add the mutated 
portion of spSPT to the reciprocally cut WT fusion to generate a quadruple mutant 
SPT fusion (x4M SPT fusion) shown in Figure 4-41 (DNA and protein sequence are 
shown in Appendix 1).  
Figure 4-41 Plasmid map of x4M SPT fusion 
 
Both the WT and x4M fusion plasmids were sequenced and found to be correct. Test 
expressions revealed the WT fusion to be easier to express at scale. The x4M fusion 
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required expression to be induced with 1 mM IPTG for 5 hours at 30 oC to produce 
the quantity of protein required for visualisation by SDS PAGE, a band at 92 kDa 
was observed and matched our prediction for the size of the fusion protein. Nickel 
affinity chromatography purified both proteins well (Figure 4-42 and Figure 4-43). 
Size exclusion chromatography showed the WT fusion to exist in a single form with 
an elution volume of 168 mL corresponding to roughly 92 kDa (Figure 4-42).   
 
Figure 4-42 Optimised purification of WT SPT Fusion 
Left - Lane 1: Low molecular weight marker, Lane 2: Pellet, Lane 3: Supernatant, Lane 4: Flow 
through, Lane 5: Wash 1 - 30 mM Imidazole wash, Lane 6: Wash 2 - 30 mM Imidazole, Lane 7: 
Elution 1 - 300 mM Imidazole, Lane 8: Elution 2 – 300 mM Imidazole. Right - Elution profile from 
Sephacryl 26/60 S300 size exclusion column, blue line showing absorbance at 280 nm. 
 
The same size exclusion chromatography for the x4M fusion showed it had 
aggregated in solution (Figure 4-43). The elution profile displayed a peak with a 
broad shoulder eluting in the void volume and therefore corresponding to aggregates 
greater or equal to 1.5 MDa. The two subsequent peaks correspond to 270 kDa 
(trimer) and the 92 kDa monomer. The small proportion of isolatable monomer 
allowed the process to be scaled and monomer isolated preferentially. Unsurprisingly 
the removal of a complete PLP binding site had affected protein folding but not 
abolished it completely. In an attempt to aid the proportion of monomer by more 
successful protein folding both the expression temperature and IPTG concentration 
were lowered with the aim of slowing protein expression and allowing more time for 
the protein to fold correctly. Cofactors are also known to increase protein folding 
efficiency but addition of pyridoxal to the growth media failed to yield a greater 
proportion of the fusion monomer.179 Mass spectrometry was attempted to confirm 
the identity of both fusion proteins but the large 92 kDa mass made this unsuccessful 







1 2 3 4 5 6 7 8 
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Figure 4-43 Optimised purification of x4M SPT Fusion 
Left - Lane 1: Low molecular weight marker, Lane 2: Pellet, Lane 3: Supernatant, Lane 4: Wash 1 - 
30 mM Imidazole, Lane 5: Elution 1 - 150 mM Imidazole, Lane 6: Elution 2 – 150 mM Imidazole, 
Lane 7: Elution 3 – 300 mM Imidazole. Right - Elution profile from Sephacryl 26/60 S300 size 
exclusion column, red line showing absorbance at 280 nm. 
 
The UV-vis spectrum of the WT fusion closely matched the monomeric spSPT 
spectrum demonstrating that PLP is bound to the enzyme in both the enolimine (333 
nm) and the ketoenamine (415 nm) forms (Figure 4-44). Addition of 20 mM L-serine 
also elicited the characteristic increase in the ketoenamine form, providing strong 
evidence that the enzyme has bound L-serine and formed a PLP:L-serine external 
aldimine.  
 
Figure 4-44 Exogenous UV-vis analysis of fusion proteins 
Left – 40 M WT Fusion before (Blue) and after 20 mM L-serine addition (Red). Right - 40 M x4M 
Fusion before (Blue) and after 20 mM L-serine addition (Red). 
 
In contrast to the WT SPT fusion the x4M SPT fusion showed no UV-vis evidence of 
binding exogenous PLP. The addition of L-serine further proved the lack of PLP by 
the inability to form the characteristically large ketoenamine peak generated from the 
formation of the PLP-L-serine external aldimine. Dialysis of the x4M fusion against 
a high (25 M) PLP buffer for 18 hours did induce limited PLP binding and allowed 
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Figure 4-45 UV-vis spectrum and kinetic analysis of fusion proteins 
A - Addition of 0.1, 0.5, 1, 2, 5, 10, 20 and 40 mM L-Serine to 10 M x4M SPT fusion. B - 
Michaelis-Menten analysis of L-Serine binding to x4M SPT fusion. C - Addition of 0.1, 0.5, 1, 2, 5, 
10 and 40 mM L-Serine to 10 M WT SPT fusion. D - Michaelis-Menten analysis of L-Serine 
binding to WT SPT fusion. 
 
Analysis of the absorbance differences at 425 nm over several L-serine 
concentrations produces an L-serine Kd for the x4M SPT fusion of 2.4 ± 0.4 mM 
(Figure 4-45A and B). The same analysis of the WT SPT fusion gave a L-serine Kd 
of 0.9 ± 0.1 mM, comparable to the monomeric spSPT (1.4 mM) (Figure 4-45C and 
D). The similarity between the monomeric and the WT SPT fusion binding 
coefficients is evidence that the head-to-tail attachment of two SPTs has no 
detrimental effect of L-serine binding. The roughly 50% drop in binding efficiency in 
the x4M SPT fusion could arise from the lack of a PLP binding site in one monomer 
causing a long range subtle conformational change in the second active site. 
Alternatively the large-scale aggregation seen via the size exclusion chromatography 
could also cause sub-optimal substrate binding.  
 
Unfortunately, the progress of the fusion project was continually hampered by the 
tendency of the x4M SPT fusion to aggregate both during expression and after size 
exclusion chromatography. Relatively pure monomer was isolated from the size 
exclusion procedure but aggregated again within hours. The ability to express pure 
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monomeric WT SPT fusion was also unreproducible. The original growth, 
expression and purification conditions were repeated diligently but the size exclusion 
chromatography always revealed a multimeric mixture. Lowering the expression 
temperature, addition of pyridoxal to the media and changing the media were all 
attempted to aid protein folding but yielded no results. The inability to purify the 
control, WT SPT fusion, or large quantities of the x4M SPT fusion rendered the 
project difficult to continue to full structural studies.  
 
These results and the work of Dunn and Ferreira suggest that the production of 
unnatural fusion proteins are possible. It is worth noting that no artificial bacterial 
fusion will ever be a 100% accurate model for the human SPT complex so any data 
produced from such a fusion will always be questioned. Therefore efforts may be 
better directed developing conditions to express and purify the challenging 
multimeric membrane bound human SPT complex. However, if the usefulness of a 
bacterial SPT fusion warrants further work, a similar approach to that of Ferreira et 
al.178 could be adopted. In this work a powerful in vivo complementation activity 
screen was developed by using E. coli cells deficient in 5-aminolevulinate synthase 
activity. They can therefore only grow when transformed with a functioning ALAS 
or ALAS fusion. If a sphingolipid producing bacterium could be made auxotrophic 
for sphingolipid biosynthesis then this could be used to screen plasmids for a 
functioning SPT fusion. A classic model system developed by Dunn and others is the 
use of yeast lcb1 and lcb2 knockouts to test the activity of SPT homologs – this 
would be a good test system. Moreover, recent work that identified the SPT involved 
in Bacteroides fragilis sphingolipid biosynthesis has suggested that this organism 
may also be an ideal model to test the ability of SPT fusions and SPT homologs from 
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5 Conclusions and future work 
Both initial aims of the myriocin project have been fulfilled. The inhibition of SPT 
by myriocin has now been shown to be competitive for both substrates, L-serine and 
palmitoyl-CoA. The Ki was determined to be 967  98 nm and the initial inhibitory 
species was identified to be a myriocin-PLP external aldimine. Moreover, myriocin 
was shown to inhibit SPT via two divergent pathways. Firstly myriocin formed an 
aldimine with PLP and bound tightly into the active site blocking substrate turnover. 
This binding of the myriocin-PLP external aldimine was non-covalent and could be 
removed through extensive dialysis. The second mode of inhibition arose from the 
myriocin-PLP external aldimine degrading in the active-site via a “retro-aldol” type 
mechanism to form a reactive long chain aldehyde which then went on to covalently 
modify the active-site lysine and again render the enzyme inactive. The classical 
initial non-covalent inhibition and the second suicide inhibition mechanism have 
been proved independently of each other through the use of mass spectrometry, UV-
vis spectroscopy and protein crystallography. The elucidation of two inhibition 
mechanisms greatly enhances the myriocin/SPT inhibition literature and gives rise to 
new opportunities for drug development. At best, this work gives rise to the 
possibility of aiding the development of a drug that inhibits SPT by being designed 
to degrade in the active site and covalently modify the enzyme. At the very least, the 
myriocin crystal structure can aid future drug development by being used in 
computer modelling. The compounds provided by Lilly can be taken forward into 
crystal trials with renewed optimism following the success of producing an SPT-
myriocin co-crystal structure.  
Through both truncation and extension of the N-terminus it has been shown that the 
as yet unknown function of the N-terminus cannot be underestimated. Both the 
removal of the first 21 amino acids and extension of the termini proved detrimental 
to the enzyme activity. Unfortunately the lack of any structural data pertaining to the 
position of the N-terminus prevents extrapolation or conjecture about its function. 
Therefore all that can be categorically stated from this work is its essential nature for 
full catalytic activity. The failure to visualise the N-terminus in either our structure or 
previously published work suggests it has a high degree of flexibility and is therefore 
incompatible with protein crystallography therefore, perhaps future advances in 
NMR structure determination will someday elucidate its mechanistic role.  
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The impressive and technically demanding work others have undertaken to develop 
fusion proteins laid a strong foundation for our work with SPT. Combining this 
previous knowledge with the proof of concept provided by Nature in the 
Coccolithovirus led to the development of two, active, SPT fusion proteins. 
Unfortunately aggregation/solubility issues dogged the development of the quadruple 
mutant fusion from the onset and in the end also hampered the characterisation of the 
WT fusion. Nevertheless, the concept of fusing proteins together is not without merit 
and could now be employed as a purification aid for the membrane bound multimeric 
human SPT complex. Fusion proteins could provide solutions to both the solubility 
issues arising from the membrane bound nature of the complex and aid the 
production of equimolar quantities of a multimeric complex which could later be 
separated, after purification, through the use of proteases. 
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Appendix 1 
Gene sequence of spSPT as published by Ikushiro99 
0000ATGACCGAAG CCGCCGCTCA GCCCCACGCC CTCCCCGCCG ACGCGCCCGA 
5100CATCGCGCCG GAACGCGACC TGCTCTCCAA GTTCGACGGC CTGATCGCCG 
1010AGCGGCAGAA GCTGCTCGAC TCCGGCGTCA CCGATCCCTT CGCGATCGTG 
1510ATGGAACAGG TGAAGTCGCC GACCGAGGCC GTGATCCGTG GCAAGGACAC 
2010GATCCTGCTC GGCACGTACA ACTATATGGG CATGACCTTC GATCCGGACG 
2510TGATCGCAGC GGGCAAGGAA GCGCTGGAGA AGTTCGGGTC GGGCACCAAT 
3010GGCAGCCGGA TGCTCAACGG CACCTTCCAC GACCATATGG AAGTCGAACA 
3510GGCGCTGCGC GATTTCTACG GCACGACCGG CGCGATCGTC TTTTCGACCG 
4010GTTACATGGC CAATCTCGGC ATCATCTCAA CGCTGGCGGG CAAGGGTGAG 
4510TATGTCATCC TCGACGCCGA CAGCCATGCG TCGATCTATG ACGGCTGCCA 
5010GCAGGGCAAT GCCGAGATCG TCCGCTTCCG CCACAATTCG GCTGAGGATC 
5510TCGACAAGCG GCTGGGCCGT CTGCCCAAGG AACCTGCCAA GCTGGTCGTG 
6010CTGGAGGGCG TCTATTCGAT GCTCGGCGAC ATCGCTCCGC TGAAGGAGAT 
6510GGTCGCGGTC GCCAAGAAGC ATGGCGCAAT GGTCTTGGTC GACGAAGCGC 
7010ATTCGATGGG CTTTTTCGGC CCCAACGGGC GCGGCGTGTA CGAGGCGCAA 
7510GGGTTGGAAG GCCAGATCGA TTTCGTCGTC GGCACCTTCT CCAAATCGGT 
8010CGGCACAGTC GGCGGCTTCG TCGTGTCCFF TCATCCGAAG TTCGAGGCGG 
8510TCCGCCTCGC CTGCCGTCCG TACATCTTCA CCGCCTCGCT GCCGCCCTCG 
9010GTGGTAGCGA CCGCGACGAC GTCGATCCGC AAGCTGATGA CCGCGCATGA 
9510AAAGCGTGAG CGGCTGTGGT CGAATGCCCG CGCGTTGCAT GGCGGGCTGA 
1001AGGCGATGGG CTTCAGGCTC GGCACCGAGA CCTGCGACAG CGCGATCGTC 
1051GCGGTCATGC TGGAGGATCA GGAACAGGCC GCGATGATGT GGCAGGCGCT 
1101GCTCGACGGC GGGCTCTACG TCAACATGGC GCGCCCGCCC GCGACCCCGG 
1151CCGGCACCTT CCTGCTGCGC TGCTCCATCT GTGCCGAGCA CACGCCGGCG 
1201CAGATCCAGA CCGTGCTGGG CATGTTCCAG GCCGCGGGCC GCGCGGTCGG 
1251CGTCATCGGC 
 
Amino acid sequence of spSPT as published by Ikushiro99 
000MTEAAAQPHA LPADAPDIAP ERDLLSKFDG LIAERQKLLD SGVTDPFAIV 
510MEQVKSPTEA VIRGKDTILL GTYNYMGMTF DPDVIAAGKE ALEKFGSGTN 
101GSRMLNGTFH DHMEVEQALR DFYGTTGAIV FSTGYMANLG IISTLAGKGE 
151YVILDADSHA SIYDGCQQGN AEIVRFRHNS VEDLDKRLGR LPKEPAKLVV 
201LEGVYSMLGD IAPLKEMVAV AKKHGAMVLV DEAHSMGFFG PNGRGVYEAQ 
251GLEGQIDFVV GTFSKSVGTV GGFVVSNHPK FEAVRLACRP YIFTASLPPS 
301VVATATTSIR KLMTAHEKRR ERLWSNARAL HGGLKAMGFR LTETCDSAIV 
351AVMLEDQEQA AMMWQALLDG GLYVNMARPP ATPAGTFLLR CSICAEHTPA 
401QIQTVLGMFQ AAGRAVGVIG  
MW = 45140 
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Gene sequence of spSPT 
0000ATGACCGAAG CCGCCGCTCA GCCCCACGCC CTCCCCGCCG ACGCGCCCGA 
5100CATCGCGCCG GAACGCGACC TGCTCTCCAA GTTCGACGGC CTGATCGCCG 
1010AGCGGCAGAA GCTGCTCGAC TCCGGCGTCA CCGATCCCTT CGCGATCGTG 
1510ATGGAACAGG TGAAGTCGCC GACCGAGGCC GTGATCCGTG GCAAGGACAC 
2010GATCCTGCTC GGCACGTACA ACTATATGGG CATGACCTTC GATCCGGACG 
2510TGATCGCAGC GGGCAAGGAA GCGCTGGAGA AGTTCGGGTC GGGCACCAAT 
3010GGCAGCCGGA TGCTCAACGG CACCTTCCAC GACCATATGG AAGTCGAACA 
3510GGCGCTGCGC GATTTCTACG GCACGACCGG CGCGATCGTC TTTTCGACCG 
4010GTTACATGGC CAATCTCGGC ATCATCTCAA CGCTGGCGGG CAAGGGTGAG 
4510TATGTCATCC TCGACGCCGA CAGCCATGCG TCGATCTATG ACGGCTGCCA 
5010GCAGGGCAAT GCCGAGATCG TCCGCTTCCG CCACAATTCG GTCGAGGATC 
5510TCGACAAGCG GCTGGGCCGT CTGCCCAAGG AACCTGCCAA GCTGGTCGTG 
6010CTGGAGGGCG TCTATTCGAT GCTCGGCGAC ATCGCTCCGC TGAAGGAGAT 
6510GGTCGCGGTC GCCAAGAAGC ATGGCGCAAT GGTCTTGGTC GACGAAGCGC 
7010ATTCGATGGG CTTTTTCGGC CCCAACGGGC GCGGCGTGTA CGAGGCGCAA 
7510GGGTTGGAAG GCCAGATCGA TTTCGTCGTC GGCACCTTCT CCAAATCGGT 
8010CGGCACAGTC GGCGGCTTCG TCGTGTCCAA TCATCCGAAG TTCGAGGCGG 
8510TCCGCCTCGC CTGCCGTCCG TACATCTTCA CCGCCTCGCT GCCGCCCTCG 
9010GTGGTAGCGA CCGCGACGAC GTCGATCCGC AAGCTGATGA CCGCGCATGA 
9510AAAGCGTGAG CGGCTGTGGT CGAATGCCCG CGCGTTGCAT GGCGGGCTGA 
1001AGGCGATGGG CTTCAGGCTC GGCACCGAGA CCTGCGACAG CGCGATCGTC 
1051GCGGTCATGC TGGAGGATCA GGAACAGGCC GCGATGATGT GGCAGGCGCT 
1101GCTCGACGGC GGGCTCTACG TCAACATGGC GCGCCCGCCC GCGACCCCGG 
1151CCGGCACCTT CCTGCTGCGC TGCTCCATCT GTGCCGAGCA CACGCCGGCG 
1201CAGATCCAGA CCGTGCTGGG CATGTTCCAG GCCGCGGGCC GCGCGGTCGG 
1251CGTCATCGGC CTCGAGCACC ACCACCACCA CCAC 
Amino acid sequence of spSPT 
000MTEAAAQPHA LPADAPDIAP ERDLLSKFDG LIAERQKLLD SGVTDPFAIV 
510MEQVKSPTEA VIRGKDTILL GTYNYMGMTF DPDVIAAGKE ALEKFGSGTN 
101GSRMLNGTFH DHMEVEQALR DFYGTTGAIV FSTGYMANLG IISTLAGKGE 
151YVILDADSHA SIYDGCQQGN AEIVRFRHNS VEDLDKRLGR LPKEPAKLVV 
201LEGVYSMLGD IAPLKEMVAV AKKHGAMVLV DEAHSMGFFG PNGRGVYEAQ 
251GLEGQIDFVV GTFSKSVGTV GGFVVSNHPK FEAVRLACRP YIFTASLPPS 
301VVATATTSIR KLMTAHEKRE RLWSNARALH GGLKAMGFRL GTETCDSAIV 
351AVMLEDQEQA AMMWQALLDG GLYVNMARPP ATPAGTFLLR CSICAEHTPA 
401QIQTVLGMFQ AAGRAVGVIG LEHHHHHH 
 
MW = 46104 Da 
 = 24780 
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Gene sequence of AmSPT 
0000ATGGGCAGCA GCCATCATCA TCATCATCAC AGCAGCGGCC TGGTGCCGCG 
5100CGGCAGCCAT ATGGCTAGCA CAGAGGCTGC CGCTCAGCCG CACGCCCTGC 
1010CTGCAGACGC GCCTGACATT GCTCCTGAAC GTGATTTGTT AAGTAAATTT 
1510GATGGCCTAA TCGCCGAAAG ACAAAAACTA CTCGATTCAG GTGTAACAGA 
2010TCCTTTTGCC ATCGTTATGG AGCAAGTTAA GTCTCCAACT GAAGCTGTGA 
2510TACGAGGAAA AGATACAATC CTGCTCGGAA CTTATAATTA CATGGGAATG 
3010ACCTTTGATC CGGACGTAAT TGCAGCAGGT AAGGAAGCAT TGGAGAAATT 
3510TGGTAGCGGT ACTAATGGTA GCAGAATGCT GAACGGGACC TTTCATGATC 
4010ATATGGAAGT TGAACAAGCC TTGCGTGATT TCTACGGTAC GACGGGAGCT 
4510ATTGTCTTTT CAACTGGTTA CATGGCAAAC CTTGGAATCA TATCAACACT 
5010TGCGGGTAAA GGTGAGTATG TTATTTTGGA TGCAGACTCT CATGCTTCTA 
5510TCTACGATGG CTGTCAACAA GGAAACGCGG AAATCGTAAG ATTCCGGCAC 
6010AACTCAGTGG AGGATCTTGA TAAGAGACTT GGTAGGCTTC CAAAGGAACC 
6510AGCTAAACTC GTTGTTTTGG AAGGCGTTTA TTCGATGCTT GGTGATATTG 
7010CTCCTCTCAA GGAGATGGTT GCTGTGGCCA AGAAGCATGG AGCCATGGTG 
7510CTTGTCGACG AGGCACATTC TATGGGCTTC TTCGGACCAA ATGGTAGAGG 
8010AGTGTACGAA GCTCAGGGAC TCGAAGGACA GATAGACTTC GTCGTCGGCA 
8510CTTTCTCTAA GTCTGTTGGA ACTGTTGGCG GGTTTGTTGT GAGCAATCAT 
9010CCAAAATTCG AGGCGGTGAG GTTAGCTTGT AGGCCATATA TATTCACCGC 
9510TAGTTTGCCC CCGAGTGTCG TAGCTACAGC TACCACATCT ATACGAAAAC 
1001TTATGACAGC GCACGAGAAA CGGGAGAGAT TATGGTCTAA TGCAAGAGCA 
1051CTGCATGGAG GGCTTAAGGC TATGGGGTTT AGGTTAGGAA CGGAGACTTG 
1101CGACTCCGCT ATTGTAGCTG TGATGCTTGA GGATCAGGAA CAAGCTGCTA 
1151TGATGTGGCA GGCCTTGTTA GATGGTGGAC TATATGTTAA CATGGCAAGA 
1201CCTCCTGCAA CCCCTGCTGG TACGTTTCTC CTACGTTGTT CCATTTGCGC 
1251TGAACACACT CCCGCACAAA TCCAGACTGT TTTGGGGATG TTTCAAGCTG 
1301CGGGACGCGC AGTCGGGGTT ATTGGT 
 
Amino acid sequence of AmSPT 
000MGSSHHHHHH SSGLVPRGSH MASTEAAAQP HALPADAPDI APERDLLSKF 
510DGLIAERQKL LDSGVTDPFA IVMEQVKSPT EAVIRGKDTI LLGTYNYMGM 
101TFDPDVIAAG KEALEKFGSG TNGSRMLNGT FHDHMEVEQA LRDFYGTTGA 
151IVFSTGYMAN LGIISTLAGK GEYVILDADS HASIYDGCQQ GNAEIVRFRH 
201NSVEDLDKRL GRLPKEPAKL VVLEGVYSML GDIAPLKEMV AVAKKHGAMV 
251LVDEAHSMGF FGPNGRGVYE AQGLEGQIDF VVGTFSKSVG TVGGFVVSNH 
301PKFEAVRLAC RPYIFTASLP PSVVATATTS IRKLMTAHEK RERLWSNARA 
351LHGGLKAMGF RLGTETCDSA IVAVMLEDQE QAAMMWQALL DGGLYVNMAR 
401PPATPAGTFL LRCSICAEHT PAQIQTVLGM FQAAGRAVGV IG 
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Gene sequence of 21 spSPT0000 
0000ATGGCACGCG ACGTGCTCTC CAAGTTCGAC GGCCTGATCG CCGAGCGGCA 
5000GAAGCTGCTC GACTCCGGCG TCACCGATCC CTTCGCGATC GTGATGGAAC 
1010AGGTGAAGTC GCCGACCGAG GCCGTGATCC GTGGCAAGGA CACGATCCTG 
1510CTCGGCACGT ACAACTATAT GGGCATGACC TTCGATCCGG ACGTGATCGC 
2010AGCGGGCAAG GAAGCGCTGG AGAAGTTCGG GTCGGGCACC AATGGCAGCC 
2510GGATGCTCAA CGGCACCTTC CACGACCATA TGGAAGTCGA ACAGGCGCTG 
3010CGCGATTTCT ACGGCACGAC CGGCGCGATC GTCTTTTCGA CCGGTTACAT 
3510GGCCAATCTC GGCATCATCT CAACGCTGGC GGGCAAGGGT GAGTATGTCA 
4010TCCTCGACGC CGACAGCCAT GCGTCGATCT ATGACGGCTG CCAGCAGGGC 
4510AATGCCGAGA TCGTCCGCTT CCGCCACAAT TCGGTCGAGG ATCTCGACAA 
5010GCGGCTGGGC CGTCTGCCCA AGGAACCTGC CAAGCTGGTC GTGCTGGAGG 
5510GCGTCTATTC GATGCTCGGC GACATCGCTC CGCTGAAGGA GATGGTCGCG 
6010GTCGCCAAGA AGCATGGCGC AATGGTCTTG GTCGACGAAG CGCATTCGAT 
6510GGGCTTTTTC GGCCCCAACG GGCGCGGCGT GTACGAGGCG CAAGGGTTGG 
7010AAGGCCAGAT CGATTTCGTC GTCGGCACCT TCTCCAAATC GGTCGGCACA 
7510GTCGGCGGCT TCGTCGTGTC CAATCATCCG AAGTTCGAGG CGGTCCGCCT 
8010CGCCTGCCGT CCGTACATCT TCACCGCCTC GCTGCCGCCC TCGGTGGTAG 
8510CGACCGCGAC GACGTCGATC CGCAAGCTGA TGACCGCGCA TGAAAAGCGT 
9010GAGCGGCTGT GGTCGAATGC CCGCGCGTTG CATGGCGGGC TGAAGGCGAT 
9511GGGCTTCAGG CTCGGCACCG AGACCTGCGA CAGCGCGATC GTCGCGGTCA 
1001TGCAGGAGGA TCAGGAACAG GCCGCGATGA TGTGGCAGGC GCTGCTCGAC 
1051GGCGGGCTCT ACGTCAACAT GGCGCGCCCG CCCGCGACCC CGGCCGGCAC 
1101CTTCCTGCTG CGCTGCTCCA TCTGTGCCGA GCACACGCCG GCGCAGATCC 
1151AGACCGTGCT GGGCATGTTC CAGGCCGCGG GCCGCGCGGT CGGCGTCATC 
1201GGCCTCGAGC ACCACCACCA CCACCAC 
 
Amino acid sequence of 21 spSPT 
000MARDVLSKFD GLIAERQKLL DSGVTDPFAI VMEQVKSPTE AVIRGKDTIL 
510LGTYNYMGMT FDPDVIAAGK EALEKFGSGT NGSRMLNGTF HDHMEVEQAL 
101RDFYGTTGAI VFSTGYMANL GIISTLAGKG EYVILDADSH ASIYDGCQQG 
151NAEIVRFRHN SVEDLDKRLG RLPKEPAKLV VLEGVYSMLG DIAPLKEMVA 
201VAKKHGAMVL VDEAHSMGFF GPNGRGVYEA QGLEGQIDFV VGTFSKSVGT 
251VGGFVVSNHP KFEAVRLACR PYIFTASLPP SVVATATTSI RKLMTAHEKR 
301ERLWSNARAL HGGLKAMGFR LGTETCDSAI VAVMQEDQEQ AAMMWQALLD 
351GGLYVNMARP PATPAGTFLL RCSICAEHTP AQIQTVLGMF QAAGRAVGVI 
401GLEHHHHHH 
 
Amino acids highlighted in yellow are different from spSPT. 
MW = 44211 Da 
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Gene sequence of x4M SPT fusion 
0000ATGGGATCCG AGGCTGCCGC TCAGCCGCAC GCCCTGCCTG CAGACGCGCC 
5100TGACATTGCT CCTGAACGTG ATTTGTTAAG TAAATTTGAT GGCCTAATCG 
1010CCGAAAGACA AAAACTACTC GATTCAGGTG TAACAGATCC TTTTGCCATC 
1510GTTATGGAGC AAGTTAAGTC TCCAACTGAA GCTGTGATAC GAGGAAAAGA 
2010TACAATCCTG CTCGGAACTT ATAATTACAT GGGAATGACC TTTGATCCGG 
2510ACGTAATTGC AGCAGGTAAG GAAGCATTGG AGAAATTTGG TTCGGGAACT 
3010AATGGTAGCA GAATGCTGAA CGGGACCTTT CATGATCATA TGGAAGTTGA 
3510ACAAGCCTTG CGTGATTTCT ACGGTACGAC GGGAGCTATT GTCTTTTCAA 
4010CTGGTTACAT GGCAAACCTT GGAATCATAT CAACACTTGC GGGTAAAGGT 
4510GAGTATGTTA TTTTGGATGC AGACTCTCAT GCTTCTATCT ACGATGGCTG 
5010TCAACAAGGA AACGCGGAAA TCGTAAGATT CCGGCACAAC TCAGTGGAGG 
5510ATCTTGATAA GAGACTTGGT AGGCTTCCAA AGGAACCAGC TAAACTCGTT 
6010GTTTTGGAAG GCGTTTATTC GATGCTTGGT GATATTGCTC CTCTCAAGGA 
6510GATGGTTGCT GTGGCCAAGA AGCATGGAGC CATGGTGCTT GTCGACGAGG 
7010CACATTCTAT GGGCTTCTTC GGACCAAATG GTAGAGGAGT GTACGAAGCT 
7510CAGGGACTCG AAGGACAGAT AGACTTCGTC GTCGGCACTT TCTCTAAGTC 
8010TGTTGGAACT GTTGGCGGGT TTGTTGTGAG CAATCATCCA AAATTCGAGG 
8510CGGTGAGGTT AGCTTGTAGG CCATATATAT TCACCGCTAG TTTGCCCCCG 
9011AGTGTCGTAG CTACAGCTAC CACATCTATA CGAAAACTTA TGACAGCGCA 
9511CGAGAAACGG GAGAGATTAT GGTCTAATGC AAGAGCACTG CATGGAGGGC 
1001TTAAGGCTAT GGGGTTTAGG TTAGGAACGG AGACTTGCGA CTCCGCTATT 
1051GTAGCTGTGA TGCTTGAGGA TCAGGAACAA GCTGCTATGA TGTGGCAGGC 
1101CTTGTTAGAT GGTGGACTAT ATGTTAACAT GGCAAGACCT CCTGCAACCC 
1151CTGCTGGTAC GTTTCTCCTA CGTTGTTCCA TTTGCGCTGA ACACACTCCC 
1201GCACAAATCC AGACTGTTTT GGGGATGTTT CAAGCTGCGG GACGCGCAGT 
1251CGGGGTTATT GGTGCTAGCG AAAACCTGTA TTTTCAGGGC ACCGAAGCCG 
1301CCGCTCAGCC CCACGCCCTC CCCGCCGACG CGCCCGACAT CGCGCCGGAA 
1351CGCGACCTGC TCTCCAAGTT CGACGGCCTG ATCGCCGAGC GGCAGAAGCT 
1401GCTCGACTCC GGCGTCACCG ATCCCTTCGC GATCGTGATG GAACAGGTGA 
1451VAGTCGCCGA CCGAGGCCGT GATCCGTGGC AAGGACACGA TCCTGCTCGG 
1501CACGTACAAC TATATGGGCA TGACCTTCGA TCCGGACGTG ATCGCAGCGG 
1551GCAAGGAAGC GCTGGAGAAG TTCGGGTCGG GCACCAATGG CAGCCGGATG 
1601CTCAACGGCA CCTTCCACGA CCATATGGAA GTCGAACAGG CGCTGCGCGA 
1651TTTCTACGGC ACGACCGGCG CGATCGTCTT TTCGACCGGT TACATGGCCA 
1701ATCTCGGCAT CATCTCAACG CTGGCGGGCA AGGGTGAGTA TGTCATCCTC 
1751GACGCCGACA GCTGTGCGTC GATCTATGAC GGCTGCCAGC AGGGCAATGC 
1801CGAGATCGTC CGCTTCCGCC ACAATTCGGT CGAGGATCTC GACAAGCGGC 
1851TGGGCCGTCT GCCCAAGGAA CCTGCCAAGC TGGTCGTGCT GGAGGGCGTC 
1901TATTCGATGC TCGGCGACAT CGCTCCGCTG AAGGAGATGG TCGCGGTCGC 
1951CAAGAAGCAT GGCGCAATGG TCTTGGTCGA AGAAGCGCTT TCGATGGGCT 
2001TTTTCGGCCC CAACGGGCGC GGCGTGTACG AGGCGCAAGG GTTGGAAGGC 
2051CAGATCGATT TCGTCGTCGG CACCTTCTCC AACTCGGTCG GCACAGTCGG 
2101CGGCTTCGTC GTGTCCAATC ATCCGAAGTT CGAGGCGGTC CGCCTCGCCT 
2151GCCGTCCGTA CATCTTCACC GCCTCGCTGC CGCCCTCGGT GGTAGCGACC 
2201GCGACGACGT CGATCCGCAA GCTGATGACC GCGCATGAAA AGCGTGAGCG 
2251GCTGTGGTCG AATGCCCGCG CGTTGCATGG CGGGCTGAAG GCGATGGGCT 
2301TCAGGCTCGG CACCGAGACC TGCGACAGCG CGATCGTCGC GGTCATGCTG 
2351GAGGATCAGG AACAGGCCGC GATGATGTGG CAGGCGCTGC TVCGACGGCG 
2401GGCTCTACGT CAACATGGCG CGCCCGCCCG CGACCCCGGC CGGCACCTTC 
2451CTGCTGCGCT GCTCCATCTG TGCCGAGCAC ACGCCGGCGC AGATCCAGAC 
2501CGTGCTGGGC ATGTTCCAGG CCGCGGGCCG CGCGGTCGGC GTCATCGGCC 
2551TCGAGCACCA CCACCACCAC CAC 
Amino acid sequence of x4M SPT fusion 
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000MGSEAAAQPH ALPADAPDIA PERDLLSKFD GLIAERQKLL DSGVTDPFAI 
051VMEQVKSPTE AVIRGKDTIL LGTYNYMGMT FDPDVIAAGK EALEKFGSGT 
101NGSRMLNGTF HDHMEVEQAL RDFYGTTGAI VFSTGYMANL GIISTLAGKG 
151EYVILDADSH ASIYDGCQQG NAEIVRFRHN SVEDLDKRLG RLPKEPAKLV 
201VLEGVYSMLG DIAPLKEMVA VAKKHGAMVL VDEAHSMGFF GPNGRGVYEA 
251QGLEGQIDFV VGTFSKSVGT VGGFVVSNHP KFEAVRLACR PYIFTASLPP 
301SVVATATTSI RKLMTAHEKR ERLWSNARAL HGGLKAMGFR LGTETCDSAI 
351VAVMLEDQEQ AAMMWQALLD GGLYVNMARP PATPAGTFLL RCSICAEHTP 
401AQIQTVLGMF QAAGRAVGVI GASENLYFQG TEAAAQPHAL PADAPDIAPE 
451RDLLSKFDGL IAERQKLLDS GVTDPFAIVM EQVKSPTEAV IRGKDTILLG 
501TYNYMGMTFD PDVIAAGKEA LEKFGSGTNG SRMLNGTFHD HMEVEQALRD 
551FYGTTGAIVF STGYMANLGI ISTLAGKGEY VILDADSCAS IYDGCQQGNA 
601EIVRFRHNSV EDLDKRLGRL PKEPAKLVVL EGVYSMLGDI APLKEMVAVA 
651KKHGAMVLVE EALSMGFFGP NGRGVYEAQG LEGQIDFVVG TFSNSVGTVG 
701GFVVSNHPKF EAVRLACRPY IFTASLPPSV VATATTSIRK LMTAHEKRER 
751LWSNARALHG GLKAMGFRLG TETCDSAIVA VMLEDQEQAA MMWQALLDGG 
801LYVNMARPPA TPAGTFLLRC SICAEHTPAQ IQTVLGMFQA AGRAVGVIGL 
851EHHHHHH 
 
MW = 92477 DA 
= 49560 
TEV Protease site highlighted in green.  
Mutated PLP binding residues highlighted in yellow. 
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Appendix 2 
Peptide mass fingerprinting of the myriocin-modified SPT. Table of peptides 
assigned after LC-MS analysis of the trypsin digest of the myriocin-modified SPT 
enzyme. SPT was treated with 200 M myriocin and incubated at 25 °C overnight. 
Before MS analysis the sample was reduced with 10 mM NaBH4. Overall sequence 
coverage observed was 89%. Three species were assigned as tryptic peptides 
containing the mass 282.24 Da modification (+C18H34O2) - these are listed in bold. 
All three of these peptides span the region of the protein containing Lys265 
(highlighted in red).  
Mass 
[M+H] 
(Da) Start* End* Sequence 
2711.2842 -4 22  (R)GSHMASTEAAAQPHALPADAPDIAPER(D) 
2711.2842 -4 22  (R)GSHMASTEAAAQPHALPADAPDIAPER(D) 
3267.6063 -4 27  (R)GSHMASTEAAAQPHALPADAPDIAPERDLLSK(F) 
3267.6063 -4 27  (R)GSHMASTEAAAQPHALPADAPDIAPERDLLSK(F) 
4169.072 -4 35  (R)GSHMASTEAAAQPHALPADAPDIAPERDLLSKFDGLIAER(Q) 
4425.2256 -4 37  (R)GSHMASTEAAAQPHALPADAPDIAPERDLLSKFDGLIAERQK(L) 








1476.8057 23 35  (R)DLLSKFDGLIAER(Q) 
920.4836 28 35  (K)FDGLIAER(Q) 
2218.1788 36 55  (R)QKLLDSGVTDPFAIVMEQVK(S) 
5843.9948 36 89  (R)QKLLDSGVTDPFAIVMEQVKSPTEAVIRGKDTILLGTYNYMGMTFDPDVIAAGK(E) 
2218.1788 36 55  (R)QKLLDSGVTDPFAIVMEQVK(S) 
1962.0252 38 55  (K)LLDSGVTDPFAIVMEQVK(S) 
2815.491 38 63  (K)LLDSGVTDPFAIVMEQVKSPTEAVIR(G) 
6158.1426 38 94  (K)LLDSGVTDPFAIVMEQVKSPTEAVIRGKDTILLGTYNYMGMTFDPDVIAAGKEALEK(F) 
1962.0252 38 55  (K)LLDSGVTDPFAIVMEQVK(S) 
2815.491 38 63  (K)LLDSGVTDPFAIVMEQVKSPTEAVIR(G) 
872.4836 56 63  (K)SPTEAVIR(G) 
3644.8339 56 89  (K)SPTEAVIRGKDTILLGTYNYMGMTFDPDVIAAGK(E) 
4215.1352 56 94  (K)SPTEAVIRGKDTILLGTYNYMGMTFDPDVIAAGKEALEK(F) 
2791.3681 64 89  (R)GKDTILLGTYNYMGMTFDPDVIAAGK(E) 
3361.6694 64 94  (R)GKDTILLGTYNYMGMTFDPDVIAAGKEALEK(F) 
4225.058 64 103  (R)GKDTILLGTYNYMGMTFDPDVIAAGKEALEKFGSGTNGSR(M) 
2606.2517 66 89  (K)DTILLGTYNYMGMTFDPDVIAAGK(E) 
1452.7077 90 103  (K)EALEKFGSGTNGSR(M) 
2027.9426 104 120  (R)MLNGTFHDHMEVEQALR(D) 
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* Start and End residues are given for wild-type (without the N-terminal His-tag and 
extension) SPT protein.  
  
2923.3527 149 175  (K)GEYVILDADSHASIYDGCQQGNAEIVR(F) 
1515.7663 176 187  (R)FRHNSVEDLDKR(L) 
3735.1315 188 222  (R)LGRLPKEPAKLVVLEGVYSMLGDIAPLKEMVAVAK(K) 
3863.2265 188 223  (R)LGRLPKEPAKLVVLEGVYSMLGDIAPLKEMVAVAKK(H) 
3735.1315 188 222  (R)LGRLPKEPAKLVVLEGVYSMLGDIAPLKEMVAVAK(K) 
3408.9249 191 222  (R)LPKEPAKLVVLEGVYSMLGDIAPLKEMVAVAK(K) 
3537.0198 191 223  (R)LPKEPAKLVVLEGVYSMLGDIAPLKEMVAVAKK(H) 
3070.6931 194 222  (K)EPAKLVVLEGVYSMLGDIAPLKEMVAVAK(K) 
1917.0765 198 215  (K)LVVLEGVYSMLGDIAPLK(E) 
2645.4656 198 222  (K)LVVLEGVYSMLGDIAPLKEMVAVAK(K) 
2773.5606 198 223  (K)LVVLEGVYSMLGDIAPLKEMVAVAKK(H) 
1917.0765 198 215  (K)LVVLEGVYSMLGDIAPLK(E) 
2645.4656 198 222  (K)LVVLEGVYSMLGDIAPLKEMVAVAK(K) 
747.4069 216 222  (K)EMVAVAK(K) 
2357.1278 223 244  (K)KHGAMVLVDEAHSMGFFGPNGR(G) 
1484.7856 266 280  (K)SVGTVGGFVVSNHPK(F) 
2635.4276 286 310  (R)LACRPYIFTASLPPSVVATATTSIR(K) 
2635.4276 286 310  (R)LACRPYIFTASLPPSVVATATTSIR(K) 




1398.7634 311 321  (R)KLMTAHEKRER(L) 
3992.2908 245 280  (R)GVYEAQGLEGQIDFVVGTFSKSVGTVGGFVVSNHPK(F) 
4594.6672 245 285  (R)GVYEAQGLEGQIDFVVGTFSKSVGTVGGFVVSNHPKFEAVR(L) 
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